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Abstract 
Introduction: Acetylcholinesterase Inhibitor (AChEI) poisoning is well described in 
chemical warfare and is commonly used for attempted suicide in many third world 
countries.  
Methods: This study serves to describe the demographic factors, temporal 
relationships and causes of acetylcholinesterase inhibitor overdose at a tertiary 
hospital emergency department in Gauteng, South Africa. 
Cross sectional chart review from the adult emergency unit overdose register was 
used to extract those patients with AChEI overdose and analysed for demographics, 
temporal relationships, presenting signs and blood results, treatment regimens and 
emergency department outcomes.  
Results: Of the 126 patients with AChEI overdose during this period over three-
quarters (77%) had taken AChEI for attempted suicide. AChEI were usually taken 
alone without being mixed with other toxins, medicines or poisons. Males (54.3%) 
were more likely to attempt AChEI overdose than females. Younger people were 
more likely to overdose on AChEI with the majority (43.7%) being between 20-29 
years, 24.6% between 30-39 years and 17.4% between 14-19 years. The remainder 
were over 40 years. Miosis was the most common sign of poisoning exhibited by 
74% of patients. Emergency treatment was supportive with urgent use of high doses 
of atropine in escalating doses. Oximes and benzodiazepines were not used in the 
initial urgent treatment. Most patients (69%) were admitted to a high care, non-
ventilated ward for observation and ongoing treatment but 19% of patients were 
severe enough to be ventilated and admitted into ICU. A small percentage, (12%) 
were sent to general wards. The mortality from AChEI poisoning in the unit was 
2.4%. 
V 
Conclusion: Typically, young healthy people were found to abuse AChEIs; the 
majority of which had suicidal intent. An average of 5 patients presented with AChEI 
poisoning per week. The mortality rate in the unit was very low. 
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1 Introduction 
1.1 Motivation and rationale for this research 
Poisoning has been part of the history of mankind, in fact and legend, since 
documentation began. In 399BC Socrates was put to death by poison (hemlock) (1). 
Legend has it that Cleopatra was poisoned, and there is argument as to whether it 
was suicide or murder; and whether snake venom or another poison was used in the 
process (2). Poisoning has been recognised and used by humans throughout the 
world for millennia for hunting, warfare, suicide and murder (3). As new poisonous 
substances are found or developed they have the potential to be used or abused by 
society. Acetylcholinesterase inhibitors (AChEI), relatively recently developed in the 
early nineteenth century (4), are examples of such substances. 
 
Acetylcholinesterase inhibitors, also called anticholinesterases or cholinesterase 
inhibitors (AChEI) are found naturally and are also synthetically produced. The 
effects of some of these agents are short-acting making them attractive  compounds 
for medicinal use, for example neostigmine (used for reversal of non-depolarising 
neuromuscular blockade, and for diagnosis and management of myasthenia gravis) 
and pyridostigmine (used for treatment of myasthenia gravis) (5). The effects of other 
AChEI are irreversible or long-acting, (these compounds are toxic and are used for 
deliberate poisoning such as in chemical weapons and pesticides). 
 
In South Africa, as in other third world countries (6), clinical observation in the 
emergency departments suggests that there is continued and possibly growing 
abuse of  AChEI pesticides for deliberate self-poisoning. In South Africa these 
pesticides appear to be available in illegal packages. There is a paucity of literature 
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about the demographics of AChEI overdose in this country compared to Asian 
countries. By examining the situation in our tertiary emergency department in more 
detail and comparing it with similar situations in other countries it is hoped that we 
can draw on their experience, improve our treatment protocols and patient outcomes 
and reflect on policies in place that should control this scourge.   
 
1.2 Statement of the problem: 
It is the experience of the author that these compounds are highly abused in the 
Southern Gauteng region of South Africa and this has motivated further examination 
of the problem. 
 
1.3 Study Aim and Objectives: 
Thus, in this research report early toxic effects of synthetic AChEI pesticides 
(organophosphates (OP) and carbamates) on humans as seen in the field or in 
emergency departments, current evidence based treatment regimens and short term 
outcomes will be reviewed. The features observed during initial stabilization in the 
emergency department of a tertiary academic hospital in South Africa such as 
symptoms and signs, initial treatment protocols, the need for ventilation and mortality 
will be compared with the experiences found in other third world countries as 
described in the literature. The notification of this disease in South Africa will be 
investigated. 
  
3 
2 Literature review 
A review of the literature was conducted to understand the history of the substance 
development, then study the demographics of the problem, and to understand the 
structure, mechanisms and pathophysiology  of the compounds involved in the 
poisoning (both the poisons and the enzymes destroyed). A review of the clinical 
features of AChEI overdose, together with various investigations and management 
(both current and experimental or suggested treatments) has been performed. 
Potential causes of morbidity have been reviewed. 
 
2.1 History 
AChEI are naturally occurring compounds found in nature and include glycoalkoloids 
such as solanine and chaconine (found in potatoes, tomatoes and eggplant) (7), 
physostigmine (a carbamate found in the Calabar bean) (8) and anatoxin (an OP) 
found in blue-green algae (9). 
 
Isolation of the prototype to synthetic acetylcholinesterase inhibitors is credited to 
Swiss chemist, Franz Anton Voegeli, who worked in Berlin about 200 years ago (4). 
The French organic chemist, Philippe de Clermont, and Russian chemist, Wladimir 
Moshnin, continued this research. De Clermont described the synthesis of AChEI in 
1854 at a meeting in France. In 1936 a German scientist at Bayer®, Dr Gerhard 
Schrader, working on developing insecticide poisons, found that organophosphates 
(OP), one type of acetylcholinesterase inhibitor (AChEI), were not only lethal to 
insects but also very damaging to mammals, including humans, in minimal 
concentrations. This resulted in the development of nerve gases, firstly tabun, then 
sarin, soman, and VX, now well-known for their potential and actual use in chemical 
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warfare (10). OP were further developed for pesticide use and in 1941 were 
introduced worldwide for this purpose. 
 
In the 1950s further research of chemicals that exert anticholinesterase effects 
resulted in development of the synthetic carbamates (11). These chemicals are less 
complex than OP, generally with a shorter duration of action due to reversibility of 
the damaged cholinesterase enzyme.  
 
Over the last six decades AChEI have been used, both as pesticides and as 
chemical weapons. Two well-known chemical attacks include 1) the release of sarin 
gas by a religious sect in a subway in Tokyo in 1995 (12), where 13 people were 
killed and over 5000 injured to varying degrees; and 2) the spraying of sarin over a 
suburb in Damascus, Syria, in August 2013 where the human death toll was reported 
to be anything from 300 to 1400 (13). 
 
2.2 Structure and mechanism of interference of AChEI (OP & 
Carbamates)  
AChEIs are commonly divided into those chemical compounds that are reversible 
and those that are irreversible (14). Reversible compounds tend to be short acting 
and may be used medicinally. In this research report the reversible and irreversible 
compounds that are being studied are the ones involved in pesticide use and 
poisoning viz. organophosphates and carbamates.  
The structure of OP differs from that of carbamates. 
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Organophosphates: 
 
 
Figure 1: Organophosphate structure; adapted from Marrazza (15) 
 
Organophosphates are esters of phosphoric acid with a central phosphorus atom 
linked to oxygen (=O) (oxon), or sulphur (=S) (thion); and further groups 
(represented by R1, R2 and X; and R1 or R2 will have an alkyl group attached) as 
seen in the diagram above (16). X is the volatile or leaving group which is the group 
which has the highest chance of being displaced from or “leaving” the compound, 
thus allowing the compound to attach to other compounds. In the case of OP 
pesticides being absorbed by a living organism, this volatile group (X) allows for 
increased affinity of the OP to the cholinesterase enzymes found in human and other 
living organisms.  
 
The reaction of OP with a cholinesterase is complex (17), depending on the extent of 
the lipophilic structure and the nature of the OP (oxon or thion) (16, 17). The reaction 
also depends on the specific type of OP: for example the dimethyl phosphate 
cholinesterase complexes (like carbamates; see below) are more likely to reactivate 
than other OP. Reactivation is the process whereby the complex formed between the 
AChEI and cholinesterase enzyme degenerates so the enzyme becomes active 
again. Generally the OP-cholinesterase complex can be interfered with in the initial 
 
P 
O (S) 
R1 
R2 
X 
6 
phase (which can be only minutes, or up to hours, depending on the exact 
compound) but once one of the alkyl groups, which would be part of R1 or R2, is lost 
the complex “ages” and reactivation cannot take place (16, 17). This chemical 
information is important in understanding the use and timing of the antidotes (also 
known as reactivators): oximes. 
 
Oximes (6)(see under treatment) can only be used in OPs that do not easily 
spontaneously reactivate themselves. These antidotes – if they are going to be 
effective – must be administered before the OP-cholinesterase complex ages. Thus 
they are not recommended for use in carbamate and dimethyl phosphate poisoning 
(17) since these compounds undergo reactivation and do not age. 
 
There are over 100 different organophosphate pesticides currently on the global 
market for commercial use (18, 19). Examples include parathion (one of the oldest 
organophosphates), malathion, methyl parathion, chlorpyrifos, diazinon, dichlorvos, 
phosmet, tetrachlorvinphos, fenthion, trichlorfon (20). In South Africa there are over 
30 OP available for agricultural use as pesticides and over 40% of pesticides 
documented for use in 2002 were organophosphates (21). 
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Carbamates: 
 
Figure 2: Carbamate structure; adapted from Marrazza (15) 
 
A carbamate is an organic compound derived from carbamic acid (NH2COOH)(22). 
The oxygen (=O) bond can be replaced by a sulphur bond (=S). R1 and R2 represent 
various groups which, when attached, form the different carbamates (22). These 
include carbamate pesticides (insecticides (e.g. aldicarb, oxamyl, methomyl, 
methiocarb, propoxur) (20), fungicides and herbicides) (21); carbamate medicines 
(e.g. neostigmine) (8) and synthetic substances such as in preservatives, cosmetics 
and polyurethane polymers (e.g. foam).  
 
If a carbamate pesticide is absorbed by a living organism the reaction of carbamates 
with the enzyme cholinesterase, causes carbamylation of the active site of the 
enzyme (23). This results in an inactive cholinesterase enzyme which increases the 
acetylcholine at receptor sites and causes the clinical signs of cholinergic poisoning. 
This deactivated enzyme is able to be reactivated over a period of time on its own so 
reversal of inhibition is possible (11, 22). This is an important difference compared to 
OP where the inhibition can become permanent and is then irreversible.  
 
 
 
C 
O
  
N O R1 R2 
H
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2.3 Cholinesterases 
Both OPs and carbamates are classified at AChEI. They both interfere with the 
function of cholinesterase enzymes which break down acetylcholine after its release 
and action at the neuromuscular junctions. As a result of their differing structures 
they act on different sites of the enzyme. Thus, although they cause the same 
clinical toxidrome (see 1.5), there are slight differences in treatment regimes. 
 
Cholinesterases are a group of enzymes found in most living organisms. Their 
function is to break down the neurotransmitter, acetylcholine, once it has exerted its 
effect at the post synaptic neuromuscular junction in the peripheral nervous system 
(PNS) or nerve cell synapses in the central nervous system (CNS) of an organism. 
Acetylcholine is produced in a neuron and then released into a neuromuscular 
junction in response to a trigger; it then attaches to an activation site at the 
neuromuscular junction where it elicits a response, and is then hydrolysed by the 
cholinesterase enzyme into acetate and choline (24). 
 
Cholinesterases are divided into acetylcholinesterases, (also known as red blood cell 
(RBC) cholinesterases); and pseudocholinesterases, (also known as 
butyrylcholinesterases or plasma cholinesterases) (6, 17). RBC cholinesterases are 
produced in red blood and nerve cells and found on red blood cell membranes, 
nerve cell synapses and at neuromuscular junctions. Pseudocholinesterases are 
produced in the liver and found in plasma.  
 
Acetylcholinesterases are clinically important as they act to breakdown the 
acetylcholine at nerve and neuromuscular junctions, however the clinical significance 
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of pseudocholinesterases is not clearly elucidated(17, 18). The AChEI affect both 
enzymes(18). It is easier to test for pseudocholinesterase levels than RBC 
cholinesterase levels(6, 25) so this test is usually employed to confirm  the clinical 
diagnosis of AChEI overdose.  
 
Pseudocholinesterases (CHE) recover more quickly than RBC cholinesterases as 
they are produced in the liver on a daily basis allowing them to potentially be used to 
monitor recovery from AChEI poisoning (6). Recent studies in India correlated 
severity of poisoning with pseudocholinesterase levels (26-28) – the lower the CHE 
the more severe the poisoning. 
 
RBC cholinesterases are regenerated by the bone marrow (erythropoiesis) so 
normal levels can take up to 3 months to be re-established (6). RBC cholinesterase 
levels have been considered as a good marker of severity (29) in many studies but 
only if the blood is taken in the correct manner: the blood sample must be diluted 
and cooled immediately after being drawn to allow for accurate measurement at the 
laboratory(6). In the hospital where the study took place the laboratory does not have 
the equipment to test for red blood cell cholinesterase. 
 
It is important for the treating healthcare worker to be aware of possible tests for 
AChEI overdose (pseudocholinesterase levels verses red blood cell cholinesterase 
levels) and the differences between the two. More importantly, however, the clinician 
must realise that the decision to treat in the emergency situation is a clinical one, 
based on the history and presenting signs and symptoms. Immediate treatment 
could be life-saving depending on the severity of the overdose, and results of 
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cholinesterase levels take hours or days to return in the environment where this 
study was undertaken; and thus cannot be used to guide initial treatment. 
 
At the tertiary hospital in South Africa where the data for this present study was 
collected, the pseudocholinesterase level test cost just under R70.00 (Aug 2014); 
(emailed communication from National Health Services Laboratory (NHLS)).  
 
The normal levels for pseudocholinesterase at this laboratory are gender specific 
with normal for a male: 4620-11500 U/L and for a female: 3930-10800 U/L. 
 
2.4 Causes and epidemiology of pesticide poisoning with AChEI 
A pesticide is a product or group of products that kills or harms pests. A pest is a 
creature or plant that is destructive to plants, crops or other living entity. Pesticides 
may be divided into insecticides, rodenticides, fungicides, herbicides, (amongst 
others) all of which aim to destroy or reduce that particular type of pest.  
 
Pesticide abuse by humans is well documented. Although about 33% of a total of 
250 000 suicides worldwide per annum are believed to be the result of pesticide 
poisoning, the prevalence is probably under reported (30). It is estimated that 
between 10%-80% of these pesticide poisoning are related to AChEI overdose (6, 
31) and these are commonly OP and carbamate pesticides. 
 
Overdose can be accidental (sometimes due to occupational exposure) or deliberate 
(suicidal, homicide or chemical warfare). If chemical warfare is excluded where it is 
known that huge numbers of people can be killed in a short space of time (13) then 
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the literature usually compares those overdoses which are accidental to those where 
there is deliberate intent on an individual basis.  In epidemiological studies and 
reviews it is found that people presenting at healthcare institutions with AChEI 
overdoses are more likely to have used the AChEI for deliberate self-poisoning (6, 
32, 33) but accidental poisoning and homicides also feature (31, 34). 
 
Pesticides are abused for suicide attempts in developing countries but this abuse is 
not commonly seen in developed countries (30, 35). In the America’s and Europe, 
pesticide use for suicide is low (4,9% and 3,7% respectively) (35). The literature has 
many reports of non-accidental deliberate AChEI poisonings from Asia and Africa. In 
Asia specific reports of self-poisoning are common: India (31, 36, 37), Sri Lanka (38), 
China and Taiwan (39) and Nepal (40). In Nepal 89% of patients presenting with 
AchEI overdose were suicidal (40). In Warangal, India 96% of AChEI poisoning were 
intentional (36), and in Hyderabad, India 67,8% of AChEI poisonings were suicidal 
with an increase noted in recent years. In Karnataka, India, a study found that 68% 
of pesticide poisonings were associated with suicide, with 78% of these being OP 
(41). In another Indian study 98,6% of OP poisoning was associated with suicide 
(28). Most areas in India indicate that suicide from OP was most common but 
aluminium phosphide and endrin have also been used. In the Western Pacific where 
suicide from pesticide poisoning is extremely common (55,8%), paraquat poisoning 
was the most common. 
 
Pesticide self-poisoning is common in South America, especially amongst men, but it 
is not the most prominent cause of poisoning in females who preferred non-opiate 
analgesics/antipyretics (42). 
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Suicide from pesticides is common in Africa (22,9%) (35). Studies include Uganda 
(43), Zimbabwe (33), Tanzania (44) and Malawi (45). Specifically related to AChEI, 
Malawi had 79% fatal suicidal overdoses from OP pesticides, Kenya had “half” of 
suicidal overdoses from OP and Ethiopia had >50% from OP (35). In Zimbabwe 74% 
of AChEI poisonings were associated with suicide (33).  
2.4.1 Causes of pesticide poisoning with AChEI in the South African context 
In Durban, South Africa, at the beginning of this century a study in a provincial 
hospital showed that 75% of suicides occurred in black patients. Most commonly 
medicinal tablets were used, with ingested liquids (paraffin, cleaning agents and 
insecticides) featuring second on the list (46). There was no breakdown of types of 
pesticides used in that particular study.  
 
A study of causes of repeated attempted suicide in the Johannesburg Hospital in 
Gauteng, also at the beginning of this century, showed that 63% of people used 
medication and 33% used poisons (paraffin, pesticides and battery acid) (47). This 
study did neither report on ethnicity, nor anything further regarding the particular 
pesticides. 
 
From 2000 to 2001 a  study was conducted at the Pretoria medico-legal laboratory to 
analyse the causes of death due to drugs and toxins in the area (48). Ethnicity and 
gender were compared and it was found that of the people who died from drug 
overdoses 54.8% were black and 45% were white. Gender differences were 3:1 
male: female. Of the total 153 cases analysed for toxins, 11 of these overdoses were 
from aldicarb (a carbamate) and all were black males while no other ethnic group 
had evidence of pesticide fatalities. This study also noted that “clinical studies from 
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various hospitals in South Africa indicate that there are remarkable racial differences 
in the “poison” used”. 
 
Another study in Tshwane, South Africa (Feb 2017) (49), specific to 
organophosphate poisoning, showed that of the notified cases in the area, 51.7% 
were related to suicide attempts, 21.7% accidental and 2.4% unlawful. In the 
remainder the cause was unknown.  
 
In South African cities there is evidence that AChEI are bought illegally (20, 50), 
officially as pesticides (Figure 3). This easy access possibly permits abuse of these 
substances in this country (20). 
 
Availability of AChEI in the local Soweto jurisdiction is well known (personal 
communication with staff, patients and emergency service personnel who deliver 
patients to the MEU). These poisonous compounds are sold on street corners and 
taxi ranks in small plastic wraps in the greater urban area surrounding the hospital 
for about R5.00 per packet (currently about a third of one US$).  
 
Figure 3: Photograph of “Halipirimi” as bought on the streets of Soweto. 
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The compounds are colloquially known as “Step 1”, “Step 2”, “rat poison” or 
“Halipirimi” (a Sotho word for “The sun never sets” or, to be interpreted: you will 
never see the sun set again). “Step 1” or “Step 2” (20) refer to how quickly one can 
die: death is only one or two steps away following  ingestion of this product. (The 
name: “Rat poison” often poses a problem for inexperienced healthcare workers who 
should know there are 2 types of rat poison/pesticides: the AChEI poison and the 
Coumadin based rat poison, each of which has a different presentation and 
treatment protocol). The compounds are not labelled as can be seen from Figure 3, 
thus contain neither warnings nor instructions on how to deal with inadvertent 
exposure as required by law when poisonous products are sold to the public in South 
Africa  (51). A study done in Cape Town revealed that street vendors are either not 
aware, or do not worry about consequences of accidental exposure of these 
products, or both (52). Despite being sold as pesticides, mainly for rat and cockroach 
control in the domestic environment, the community appears to know that this 
product can be exploited for attempted suicide or homicide. 
 
In South Africa pesticide poisoning is a notifiable disease (20, 49, 53, 54), mandating 
that all AChEI overdoses be reported to the health authorities by the treating 
healthcare professional. A surveillance study in 2006 by the University of Pretoria 
School of Public Health (55) mainly looking at malaria notifications showed a very 
poor response rate for malaria notifications at that time of 34%. In the same study 
there was some awareness (60%) in the community of General Practitioners that OP 
poisoning was notifiable but whether this pesticide problem was notified was not 
documented. In Cape Town there is evidence that pesticide poisonings are 
underdiagnosed and under reported (20). A new study (Feb, 2017) in Tshwane also 
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highlights the problem with under reporting of this disease (49). These authors 
mention the fact that the notification system is passive and paper based which might 
contribute towards the poor response rate. 
 
2.5 Demographics of overdose with AChEI 
2.5.1 Mortality associated with AChEI Overdose 
It is estimated that over 200 000 people in the world die of AChEI poisoning every 
year (6).  
 
Mortality in the acute period following overdosing is caused by a combination of 
muscle weakness and excessive secretions resulting in hypoxia and respiratory 
arrest (16). Severe bradycardia in conjunction with hypoxia may also lead to cardiac 
arrest (56) (See under Toxidrome, 2.5). 
 
In studies of AChEI poisoning in humans which have been documented from the end 
of the 20th century mortality has been documented to vary between 10-51,2% (36, 
39) but has been decreasing to 10-20% this century ostensibly due to better 
pesticide regulation and control. The higher mortality is associated with ICU 
admissions which involves the severe overdoses, so this is a small cohort of patients 
presenting with AChEI poisoning (39). An overall international mortality after AChEI 
(OP) overdose has been reported at 15% in 2008 (6). A 27% mortality was reported 
in Uganda (43) at the turn of the century (personal communication with author). A 
mortality of 8,3% was documented in Zimbabwe from 1995-2000 (33); and 5,6% 
(2006) - 7,8% (2000-2005) in two studies for acute pesticide poisoning – 
16 
predominantly associated with OP – in Tanzania (44). The case fatality rate in the 
recent study in Tshwane was 3.7% (49). 
 
In studies comparing accidental or occupational fatalities with non-accidental 
(suicide) fatalities there was a much higher incidence of death in those people who 
used AChEI to commit suicide versus those who had accidental exposure. For 
example in one area in India (36) a 77% success rate was described for suicides 
from OP overdose. In China successful suicides from OP overdose was 8,68% 
versus 0,58% from occupational exposure (57), and in Tanzania (44) the fatality rate 
from suicide attempts with pesticides (of which OP comprised the majority) was 
significantly higher than from other accidental pesticide poisonings. 
 
2.5.2 Gender differences 
The literature highlights a gender difference with more male than female AChEI 
misusers in some studies (36, 39, 41, 42, 49). These include India in general (36), 
Karnataka, India (28, 41), Taiwan (39), Tshwane, South Africa (49) and many other 
big cities worldwide (42). However this is variable, with other studies finding a 
preponderance of females such as in Tanzania, Turkey, Nepal, Hyderabad, India 
and Yuncheng, China and in China in general (37, 40, 42, 44, 57, 58); in one 
Zimbabwe study there was a statistically equal gender distribution (33). Thus, 
worldwide, there does not appear to be a clear pattern for gender distribution with 
different sites having different results (59).  
Most studies did not compare fatality rates between genders  but in one report from 
China (57), although overdosing was more common in females, the case fatality was 
higher in male misusers. 
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2.5.3 Age distribution 
In general in all studies accessed, younger adults were more likely to be the victims 
of overdosing with AChEI with the majority aged between 21-30 years: 82% in 
Zimbabwe (33), 44,5%, 46,9% and 24% respectively in different studies in India (36, 
37, 41) , and 65% in Nepal (15-30 years) (40).  In Davangere, Karnataka, India it 
appears that people involved in AChEI poisonings are slightly older (31-40 years) 
(59), while in China they are even older: 35-59 years (57). Most studies documented 
all suicides/para-suicides from AChEIs in people under 65 years. 
 
2.5.4 Temporal distribution of AChEI overdose 
Few studies could be found that detailed the timing of overdoses with regards to day, 
month or season. 
 
In India one study (60) noted an increased proportion of overdoses over weekends, 
with Saturday (27.8%) more common than Sunday (20.4%), and winter more 
common than summer (54.38%). Another study in India noted an increase in 
incidence in August and February (36). 
 
Amongst children in Cape Town, South Africa, OP and carbamate poisoning was 
more predominant in summer (50). In Tshwane, South Africa, there was a seasonal 
predominance in spring (27.5%) and summer (25.6%), and more people overdosed 
on a Sunday (21.5%) or Monday (21.5%) (49). 
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2.5.5 AChEI overdose in pregnancy 
Seldom is pregnancy related AChEI overdose reported in the literature (61). 
However, given that young females do attempt suicide and work in an agricultural 
environment there are individual case reports and small studies addressing this 
problem. Both suicide (62) and accidental agricultural exposure (63) are documented 
in case reports, however no large studies were found comparing deliberate versus 
accidental exposure to AChEIs in pregnant females. 
 
It has been documented that OP can cross the placental barrier but there appears to 
be no evidence of teratogenicity from these compounds in humans at birth (61, 64), 
nor of long-term pregnancy related sequelae, e.g. premature labour (65). There is 
also no evidence that atropine is harmful to the foetus (66). Further, it is postulated 
that progesterone may be of benefit to assist the continuation of pregnancy (67). 
However most pregnant patients who survive the acute OP overdose carry the 
foetus to term, barring other pregnancy related conditions (61), without the use of 
progesterone. There is a single case study of a pregnant patient with AChEI 
overdose where the death of the foetus may have resulted from delayed treatment of 
the overdose (68). In general, rapid treatment of AChEI poisoning has allowed 
continuation of the pregnancy to term (61, 68). 
 
2.6 Clinical Presentation 
2.6.1 Signs and symptoms of AChEI toxicity (toxidrome) 
AChEI poisoning usually presents with acute signs, the constellation of which 
constitutes a toxidrome. A toxidrome is defined as a set of signs and symptoms 
observed in a patient (or other mammal), commonly caused by a specific toxin or 
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group of toxins (69, 70). The toxidrome of AChEI is clinically indistinguishable 
between OP and Carbamates (6). 
 
The early signs of AChEI overdose can be divided into 3 categories of acetylcholine 
activity (6, 16) 
These include: 
 muscarinic overactivity in the body external to the central nervous system (CNS),  
 nicotinic overactivity in the body external to the CNS, 
 neurological effects within the CNS. 
Muscarinic acetylcholine receptors are the end receptors found in the postsynaptic 
space of (mainly) parasympathetic nerves and they are stimulated by the release of 
acetylcholine from the nerves into this space. (The exception is the sweat glands 
which are stimulated by sympathetic nerves which have muscarinic receptors, as 
opposed to the expected nicotinic receptors (56) (see below)).  
Muscarinic effects from AChEI overdose or poisoning are the most obvious and are 
usually the first and most prominent signs to be observed with an incidence of 82-
83% (29, 71). They are often dramatic and when severe this is termed a cholinergic 
crisis. These physiological muscarinic effects manifest as a bundle of typical features  
which together represent the classical AChEI toxidrome, features of which are easily 
recalled using the well-known mnemonic “DUMBBELSS”: diarrhoea, urination, 
miosis causing blurred vision, bradycardia, bronchorrhoea and bronchospasm, 
emesis (vomiting), lacrimation, salivation and sweating (16). 
 
A table has been constructed below to show muscarinic effects in various studies 
referenced, (28, 58, 72, 73). As can be seen miosis has a high percentage incidence 
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for muscarinic signs documented for AChEI overdose in all the studies and can be 
considered a “strong indicator” for AChEI poisoning (74). 
 
Table 1: Some significant muscarinic effects found in various studies 
Country/ 
Reference 
Diarrhoea Urination Miosis 
Broncho- 
rrhoea 
Brady- 
cardia 
Vomiting 
(Emesis) 
Lacrimation 
Hyper-
salivation 
Sweating 
India (28) 58.6% 58.6% 93.2% -* 24.8% - 86.4% 86.4% - 
Turkey (58) 2.7% 2.7% 78% 54.6% 5% 32.7% - - 28.6% 
India (72) 6% - 89.4% 78% - 74% 4% 26% - 
Egypt (73) 100% - 74.5% 81% 49% 96% - 72% 76.6% 
*: “ – “ refers to no data for this effect in study referenced. 
Nicotinic acetylcholine receptors are end receptors found at pre and post synaptic 
sites of neuromuscular junctions in the peripheral nervous system (PNS) as well as 
in the CNS of mammals. These nicotinic acetylcholine receptors are stimulated via 
the autonomic sympathetic nervous system in the PNS (with the exception of sweat 
glands, whose stimulation is via the sympathetic system but whose receptors are 
muscarinic (56)). 
 
Nicotinic effects reduce muscle activity and effectiveness causing muscle weakness. 
Muscle fasciculations may also be seen. This often involves the respiratory system 
and may result in depressed breathing (56). Together with the increased secretions 
there can be severe hypoxia which may result in cardiac arrest and death of the 
patient. Other nicotinic effects are tachycardia, mydriasis (dilated pupils) (noted in 
16% of patients in one study (72)) and hypertension(16, 56). These are opposite to 
the muscarinic effects and the interactions between the two may confuse the 
diagnosis. Nicotinic effects are usually the least likely to be observed initially,17% 
and 24% noted respectively in two studies (29, 71). Fasciculations were noted in 
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55.3%, 24% and 8.2% of patients respectively in three studies (58, 72, 73), while 
muscle weakness was noted in 10% of patients in one study (72) where presenting 
features were indeed documented. The problem with lack of observation and/or 
documentation of nicotinic effects is that the muscle weakness appears to be missed 
and thus potentially ventilation is inadequately supported, which may lead to 
respiratory failure and death. Clinically muscle weakness should be documented by 
checking neck flexor muscles by lifting the head up against a force such as counter 
pressure exerted by the examiner’s arm for 10 seconds. Feeble neck flexor muscles 
correlate with significant muscle weakness and thus indicate a good chance of 
respiratory failure (75). 
 
Acute neurological effects related to interference with acetylcholine breakdown in the 
CNS include anxiety, restlessness and tremors, possible seizures and coma (16, 56) 
and appear to be more common than nicotinic effects. Altered sensorium was noted 
in 33.8%, 36%, and 78% of patients at presentation in three studies (28, 29, 71). 
Seizures were noted in patients in two studies: 1.8% and 10.6% (58, 73) where 
presenting features were documented. Poor neurological status as measured by the 
Glasgow Coma Scale (GCS) has also been found to predict severity in some studies 
(41, 76) –  a lower GCS has a higher correlation with fatality.  
 
It is possible that OP may interfere directly with thermoregulation within the CNS with 
hypothermia possibly being an initial sign of OP overdose (77). However, it must also 
be remembered that sweating caused by the muscarinic over activity will cause a 
drop in body temperature as evaporation takes place. 
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There is evidence that exact presentations of the poisoning depend on the specific  
AChEI taken as each pesticide has different fat solubility and metabolism (78). 
  
In acute poisoning such as would occur in chemical warfare, suicide or homicide, or 
accidental overdose from agricultural exposure during spraying of crops for pest 
control, the diagnosis of AChEI poisoning is clinical (16) and needs to be made on 
potential history of exposure together with signs and symptoms consistent with the 
toxidrome. Treatment must be started immediately to prevent deterioration and 
possible death.  Possible laboratory confirmation with pseudocholinesterase or RBC 
cholinesterase can be considered but will be retrospective (6, 79). 
 
2.6.2 Acute blood abnormalities 
Blood abnormalities found in acute AChEI poisoning are numerous(25). 
Hypokalaemia (25, 28, 72) from potassium loss consistent with the excessive 
secretions is common, and adds to the weakness seen with the nicotinic effects of 
the poison. Stress response blood abnormalities include hyperglycaemia, 
leucocytosis and ketonuria. Leukocytosis has been shown to be significantly raised 
in OP poisoning (58, 80) and has been postulated to be a potential mechanism for 
survival. Hyperglycaemia has been documented in a study in Turkey (58), in 66% of 
OP overdoses in a study in South Korea (81), and 27,4% in a study in Nepal (71).  
 
Lactate and pH may represent possible laboratory markers for severity (82, 83). It 
should be noted that, after an Australian study in 2001 and a review in 2010, it is 
considered acceptable practice to check pH in venous blood gases in emergency 
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departments as correlation between pH in arterial versus venous gases is good 
(95%) (84, 85).  
 
2.6.3 ECG changes 
Bradycardia as a direct result of muscarinic stimulation is considered a classic sign 
of AChEI overdose. However, tachycardia (36), (15% of cases in one study (40)) or 
normal sinus rhythm are often documented when the patient is first seen by a 
healthcare worker (86). Other ECG changes that have been documented in AChEI 
overdose include atrial fibrillation and prolonged heart rate corrected QT intervals 
(QTc), ST elevation, T wave inversion, prolonged P-R interval and rarely ventricular 
tachycardia (40, 87). No study documented Osborn waves associated with 
hypothermia. 
 
Postulated reasons for ECG (cardiac) abnormalities could include hypoxia, acidosis, 
electrolyte abnormalities (e.g. hypokalaemia), autonomic over-activity and direct 
toxic effects of the AChEIs on the myocardium (40). 
 
The use of corrected QT intervals (QTc) after initiation of treatment for the toxin have 
been studied by various authors (88). The studies with slightly larger sample sizes 
show an increase in mortality when there is a prolonged QTc. However, it is possible 
that the prolonged QTc correlates with age related cardiac changes or chronic 
diseases over and above the poisoning; and therefore QTc prolongation may rather 
be a correlation between age and chronic diseases and not directly related to the 
poison. 
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2.7 Management 
2.7.1 Decontamination 
AChEI are poisons that have the ability to be absorbed via the skin, respiratory tract 
and gastro-intestinal tract (28). Each type of AChEI varies in this regard with 
carbamates generally having lower dermal toxicity than OP. Thus healthcare 
practitioners need to be aware of the risks of contamination when treating patients 
with probable AChEI overdose.  
 
General precautions such as gloves, protective shoes and goggles are sufficient for 
instances when only gut contamination has occurred and the patient presents out of 
the contaminating environment (such as arrival at a hospital after a suicide attempt) 
(6). This would be considered level D protective clothing (89) (See Table 2 below). 
However for practitioners responding in any contaminated environment, full 
protective wear will be needed. In third world countries where resources are limited it 
has been suggested that first responders to a contaminated site at least wear rubber 
gloves and a face mask containing a charcoal filter, and skin contact should be 
avoided until decontamination has been completed (90). This would be considered 
level C protective clothing. In first world countries or if a mass AChEI attack is 
suspected level A protective clothing must be used to go into a contaminated site 
and level B protective clothing used for decontamination outside the contaminated 
area before transferral to a healthcare facility (91). Patients who present from 
contaminated environments will need to be stripped of all clothing and washed down 
with soap and water, or use bleach (90), to reduce further exposure to themselves 
and caregivers (19). 
 
25 
Table 2: US system of defining protective clothing as per their Occupational Safety 
and Health Administration (adapted from Byers et al (89)). 
Level Description 
Level A 
Highest level of protection: fully encapsulated suit developed to 
withstand the chemical expected/encountered. Full face self-
contained breathing apparatus. Generally not designed for 
flammable atmospheres 
Level B 
Similar to Level A: Full face self-contained breathing apparatus, 
but less skin protection 
Level C 
Chemically resistance clothing, googles, shoes and air-
purifying respirator. 
Level D 
Coveralls only, googles but no respiratory protection. 
 
As patients generally vomit after AChEI overdose, a naso- or oro- gastric tube may 
not assist in emptying the stomach (16). The active process of vomiting usually 
forces stomach contents to bypass the tube and clears the stomach anyway. 
However, if the patient’s airway is protected, the gastric tube must be inserted to 
ensure and maintain an empty stomach so as to reduce risk of aspiration. Gastric 
lavage should only be considered in awake patients who have taken the poison 
within the last 2 hours and are fully co-operative, or who have an endotracheal tube 
in situ to ensure airway protection (86). There is no indication for forced gastric 
lavage (43, 74, 92). Ipecacuanha is not recommended to induce emesis due to the 
risk of lowered level of consciousness that may develop due to the toxidrome, 
resulting in an increased risk of aspiration (74). 
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Some authors do not consider single dose activated charcoal useful for 
organophosphate poisons as its adsorptive capacity is too low to be of benefit (5) 
and advantages  have not been demonstrated (74, 93, 94). There is a risk of 
aspiration of the activated charcoal after atropine-induced ileus (95). However, one 
study on mice with OP overdose (dichlorvos) did show benefit after immediate 
treatment of activated charcoal (96) so other authors postulate it may be of benefit. 
 
In general, the role of multi-dose activated charcoal has not shown clear benefit in 
any overdose (97). It has been considered in phenobarbitone, carbamazepine, 
dapsone, quinine and theophylline and has not been recommended in AChEI 
overdose (70). 
 
For reference the dose of activated charcoal in adults would be 50g in 400ml water 
to be drunk or passed an oro- or nasogastric tube and then, if the multi-dose regimen 
is instituted then the dose would be repeated at 25g every 2 hours or 50g every 4 
hours until toxic levels are down in the above drugs mentioned, or the patient 
improves clinically (70). 
 
2.7.2 Treatment  
Treatment of AChEI poisoning can be divided it symptomatic (supportive) treatment 
and poison specific management. 
 
2.7.2.1 Symptomatic treatment 
Symptomatic treatment involves the standard initial assessment and management of 
airway, breathing and circulation (A, B, C) (6, 16, 86). When the patient presents, 
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these parameters may or may not be reasonably controlled. If patients with 
suspected overdose are awake and communicating, they can be placed laterally, 
suctioned, vital signs taken, intravenous access achieved and specific management 
started. If any of the above parameters are abnormal, each should be dealt with 
specifically. 
 
Full airway management may be needed which might include intubation and 
ventilation depending on the severity of the symptoms. Most patients will not require 
definitive control via endotracheal intubation with positive pressure ventilation but 
those who present with hypoxia and excessive pulmonary secretions and/or deep 
coma warrant this management immediately (6, 16).  
 
If patients present in deep coma (Glasgow Coma Scale (GCS) of 3 with no facial 
muscle activity), or are gasping, they should then be intubated immediately. The 
cardiac arrest patient in this context should have some form of advanced airway 
placed early in the resuscitation once CPR and defibrillation have been instituted. In 
all instances, supraglottic airway devices could be considered by inexperienced 
personnel (38). Usually in this situation no drug support is needed to achieve airway 
control. However, other patients such as those with fasciculations, GCS of 4-8/15 , 
and those with copious secretions and hypoxia may need drug support to facilitate 
intubation – in these cases rapid sequence intubation (RSI) should be used. 
 
During RSI a combination of an induction sedative/hypnotic agent and a rapidly 
acting muscle relaxant is used. The choice of induction agent will depend on the 
patient characteristics and what is available to the healthcare practitioner at the time. 
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Generally one of the agents: etomidate or ketamine will be used depending on the 
age, any known chronic morbidities and blood pressure of the patient (98).  
The benefits of ketamine are its ability to cause bronchodilation and 
sympathomimetic effects. If there is a cholinergic crisis, the increased secretions that 
could be induced by ketamine under normal intubation conditions are not usually an 
added problem due to two factors: 1) the receptors are maximally stimulated by the 
AChEI poison so secretions cannot increase; 2) atropine is already used, which is 
the agent used to reduce secretions (98). Ketamine is used in AChEI research and 
has been found to reduce the problems of ongoing seizure activity (99). 
 
Propofol and thiopental sodium should be considered with caution due to their 
cardiac depressive effects. Thiopental can also increase the chance of 
bronchospasm. Both cardiac depressive effects and bronchospasm are common in 
AChEI poisoning so these induction agents are potentially best avoided (98). 
 
Suxamethonium, which is the muscle relaxant usually used for RSI, is best avoided 
in AChEI poisoning. The mechanism of suxamethonium breakdown is via the 
enzyme, pseudocholinesterase, which would have been damaged or destroyed by 
the poison (5, 16), thus causing a “scoline apnoea” type situation. Rocuronium (a 
non-depolarising muscle relaxant) is usually considered the best muscle relaxant for 
RSI in AChEI overdose (38). Initial studies with this drug suggest that, by blocking 
the neuromuscular receptor with a non-depolarising neuromuscular blocker there 
may be less damage at the neuromuscular junction, less long-term ventilation 
required and fewer complications (38, 100). The current recommended dose of 
rocuronium for RSI is 1,2mg/kg. Given that the number of unbound acetylcholine 
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receptors is reduced because of the AChEI poisoning and the patients’ muscles are 
weakened it is probable that such a high dose is unnecessary, so a dose compatible 
with the ampoules available within the range of maintenance and maximum dose 
(0,6-1,2mg/kg) is probably sufficient (personal observation). In normal subjects an 
80% block of receptors is achieved at 1 minute with a dose of 0,6mg/kg (101). No 
recommendations for dosing of rocuronium in AChEI poisoning could be found in the 
literature. (Studies done in myasthenia gravis pigs who have reduced acetylcholine 
receptors show a need to reduce rocuronium, and this is practiced in the 
anaesthesia of such patients) (102, 103).  
 
Circulatory support with fluids may be needed if large volumes of fluids have been 
lost due to excessive secretions (diarrhoea, sweating and urination). Potassium may 
be depleted from the intravascular space due to the secretions lost, supplementing 
the weakness seen from nicotinic interference, and should be replaced as needed 
(28). A few patients may need vasopressors for continued hypotension. There is 
evidence that different OPs may cause different degrees of symptomatology which 
may lead to different needs in treatment. One OP where treatment of hypotension 
was problematic was dimethoate (78). Here, despite atropine, oximes and 
vasopressors, hypotension was not always manageable and 35 out of 60 patients 
who died, died of hypotensive shock. In most patients with hypotension there is a 
good response to atropinisation (see specific treatment below).  
 
Other symptomatic treatment recommended acutely is the use of benzodiazepines 
(16), the most well-known of which is diazepam, with much experience in its use, 
and probably the cheapest worldwide. Diazepam reduces anxiety and the 
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fasciculations seen in AChEI overdose, controls seizures (16) and it has been found 
in monkeys to reduce some of the later chronic muscle and neurological 
complications of AChEI overdose (104). In 2 studies, rats experimentally pre-treated 
with diazepam just before OP exposure showed improved 10-minute survival 
compared to those who did not get the diazepam pre-treatment (105, 106). If 
ipratropium bromide or glycopyrrolate was added, there was a significant 
improvement in 24-hour survival (105). Benzodiazepines, beyond the above 
mentioned possible benefits, are useful to sedate patients who have been intubated. 
Usually the short-acting benzodiazepine, midazolam, is used post intubation. 
Midazolam is likely to become the benzodiazepine of choice for the future because it 
has the shortest action and the same or better effects as compared to diazepam (13, 
107). 
2.7.2.2 Specific treatment 
Specific treatment involves urgent use of atropine (16) which competitively blocks 
muscarinic receptor sites throughout the body (rapid atropinisation). This prevents 
the ongoing stimulation by acetylcholine (which cannot be hydrolysed by the 
acetylcholinesterase that has been damaged by the AChEI) and reduces the over 
secretory and other muscarinic signs caused by the poisoning. If a patient is seen 
with the cholinergic crisis of AChEI overdose (as described in 2.6.1), atropine should 
be administered as soon as possible. Do not delay atropine while assessing the 
A,B,C’s mentioned above (108). Treat symptomatically and give atropine 
simultaneously.  
 
Atropine is rapid acting (onset is usually within one minute) and crosses the blood 
brain barrier. (AChEI poisons cross the blood brain barrier). The dose of atropine is 
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given as 0,02-0,05mg/kg intravenously (IV) (1.8mg-3mg in Bangladesh in the initial 
study where atropine ampoules are 0.6mg) (86) as soon as intravenous access is 
available. In South Africa atropine is generally available in 0,5mg and 1mg (1ml) 
ampoules. The initial target is to treat the life-threatening complications of the 
muscarinic over-activity: dry the respiratory secretions and reverse the bradycardia if 
present (86). Other secretions usually dry up during this time. Generally miosis is 
late to respond so is not the target of initial management. The patient should be 
monitored for 5 minutes and if the signs have not abated, a second dose of atropine, 
at double the initial dose, should be administered IV (6, 86). A third or further doses 
may be needed (recommended at double the previous dose). This is escalating 
atropinisation. This has been shown to be a more efficient and effective way to treat 
patient than the older regime of slow atropinisation (109, 110). 
Once initial control of respiratory secretions and haemodynamic stability is obtained, 
an atropine infusion is started. It should run at a dose of 10-20% of the total initial 
dose of atropine per hour, titrated to control signs of poisoning (86). This dose can 
be increased or further boluses can be given if muscarinic signs reappear. The 
patient needs to be monitored for reappearance of signs (too little treatment) or if 
signs of atropine toxicity emerge (too much treatment).  
 
A test dose of atropine can be considered in those patients who show minor or non-
specific symptoms, or if the diagnosis is uncertain. This involves giving 1mg atropine 
and observing for aggressive development of a tachycardia (increase of 20-25 beats 
within a minute) and/or skin flushing. Generally, if a patient has an AChEI overdose 
the tachycardia response is limited, whereas if there is no AChEI block, the patient 
shows an immediate and aggressive tachycardia (86). 
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Signs of atropine toxicity include restlessness, agitation or anxiety, confusion, 
pyrexia (86). Urinary retention is also a sign but if the patient is catheterised it cannot 
be noted. (Due to this complication all patients getting high dose atropine should be 
catheterised). Other causes of restlessness, agitation and pyrexia such as hypoxia 
and secondarily infected aspiration pneumonia must be considered. Change in pupil 
size from pinpoint to dilated may help distinguish between atropine toxicity and other 
causes, as, if pupils are becoming dilated this is evidence that the patient is 
becoming atropinised (i.e. the atropine is overcoming the AChEI toxicity). If the 
pupils are still pinpoint, then the cause of restlessness cannot be due to atropine 
toxicity as the atropine has not overcome the AChEI overdose. Infusions can be 
weaned as evidence of atropinisation occurs, and can be continued provided no 
further evidence of toxicity is noted. This can take from 12 hours to 4-5 days, or even 
longer in some cases. 
 
Glycopyrrolate (111) is also an anticholinergic muscarinic receptor blocker. It has a 
slower onset of action and does not cross the blood brain barrier (16), but is a very 
potent inhibitor of respiratory secretions. It can replace atropine later in the treatment 
of AChEI poisoning when signs of atropine central nervous system over activity start. 
Glycopyrrolate will reduce the confusion patients develop due to over-atropinisation. 
However it will be an ineffective antagonist for lipid soluble AChEI that cross the 
blood-brain barrier, and could increase seizures or coma (100). A small study 
comparing glycopyrrolate with atropine did not show any difference in mortality or 
need for intubation (112). It should not be used initially. It is more expensive than 
atropine and not always as easily available in South Africa. 
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Oximes are considered the specific antidote for organophosphates. They are not to 
be used for carbamates (5) however as there is potential for the oxime to attach to 
the acetylcholinesterase enzyme and further damage it. Oximes do not cleave the 
carbamate-enzyme bond. The carbamate-enzyme complex is weak and reversible 
and therefore the complex, over time (usually within 24-48 hours), returns to the 
separate entities and does not age (16).    
 
Many oximes have been developed and studied but none appear to be effective 
against all organophosphates (17). There is debate in the literature about the clinical 
benefit (19, 38, 43, 113, 114). A meta-analysis in 2006 (115) showed no benefit and 
possible harm. However, some authors argue that larger doses (113) are needed 
while others argue that it depends on the exact OP (114)  as to the efficacy of the 
oxime. Most trials have tested the effects of pralidoxime. These trials have yielded 
different results (38, 113, 114). The latest Cochrane review from 2011(116) 
summarizes the literature findings and suggests that there are benefits with the 
oximes if they are used early in patients seriously poisoned by diethyl OP. The 
current recommended World Health Organization dosing (pralidoxime 30mg/kg bolus 
followed by 8mg/kg/hour) is not supported by the Cochrane review of current 
research. However, there was no consensus from any randomised controlled trials 
nor recommendation for another dosing regimen and it is suggested that use is 
limited to trials and “situations where better established treatments have proven 
ineffective”. 
 
Presently the only oxime available in South Africa is obidoxime, which must be 
ordered on a patient by patient basis in state hospitals as it is no longer on state 
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tender (personal communication with Merck: manufacturer of obidoxime). Thus 
oximes were, and currently remain unavailable for use in the tertiary institution under 
study in this research report.  
 
The dose of obidoxime is 250mg in adults, (3-5mg/kg) as slow intravenous injection 
to start 5 minutes after the first dose of atropine has been given (5). It can also be 
given intramuscularly. Thereafter a continuous infusion of 750mg in 24 hours for 
adults can be continued as needed (Toxogonin® leaflet) (100). 
 
2.7.3 Experimental treatments  
A single dose of nebulised Salbutamol (or other inhaled beta 2 stimulant) might help 
improve oxygenation as it has been postulated to increase removal of alveolar 
secretions via epithelial sodium channels, while the atropine dries up secretions 
higher up the respiratory tract (38, 100). Ipratropium bromide, an anticholinergic 
agent given via nebulisation, has also been recommended (16). 
 
From the 2005 Cochrane review, a small trial using sodium bicarbonate in OP 
overdose found some benefit in alkalinisation of the blood to a pH of 7,5 using high 
doses bicarbonate (6, 117). Some countries such as Brazil and Iran are employing 
this approach (74) but further research is still required to confirm these findings. 
 
Magnesium sulphate (MgSO4) has been posited to improve prognosis in OP 
overdose as it blocks calcium channels and thus prevents acetylcholine from being 
released from presynaptic terminals (74, 100, 118). A small study showed a reduced 
mortality when MgSO4, 4g given over a 24hours period on the first day after 
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poisoning was added to the standard treatment as described above (6, 119). 
However, another study showed misrepresentative effects when MgSO4 was used to 
control seizures in sarin-exposed rats, as it blocked visualisation of seizures but did 
not prevent cortical damage due to ongoing occult brain seizures following the sarin 
exposure (120). A further small study (121) acknowledges that magnesium sulphate 
is safe and was shown to reduces mortality if given up to 16g in 4g infusions 4hourly 
during the first 24hours after AChEI poisoning. The two human studies were small 
with 50 or less participants so it is difficult to recommend giving either of these doses 
of MgSO4 to patients, but if standard practices are not working this could be 
considered. High dose MgSO4 with controlled monitoring is used with success in 
other conditions such as Eclampsia. Further work needs to be done with MgSO4.  
 
Fresh frozen plasma (FFP) has been proposed to be of benefit because it will 
increase pseudocholinesterase (74, 122) which then scavenges the OP out of the 
system. There is a small benefit of volume replacement from FFP as well, but this 
must be outweighed by the risk of blood-borne disease transmission. 
 
Haemodialysis may be of benefit in OPs with poor fat solubility (e.g. dichlorvos) 
(6, 74). 
 
In recent years lipid emulsions have become popular for certain toxins. It has been 
suggested that the emulsion may be beneficial for OP that are lipid soluble (123). A 
minor benefit was noted in a rat study (124) where time to apnoea was prolonged but 
not prevented. The only known human case report did show benefit (125). In this 
report, despite full treatment for AChEI overdose a patient deteriorated, developed 
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arrhythmias and arrested. She did not respond to standard resuscitation measures 
but a pulse returned after intralipid emulsion therapy was instituted. The patient 
survived to discharge. 
 
2.8 Risk factors for prognosis 
Risk factors for a worse prognosis that have been reviewed in the literature include: 
respiratory depression (78), coma (76), severe hypotension (78); obesity (126); 
prolongation of heart-rate corrected QT intervals (88) and poor APACHE II scores 
(29, 41, 127). RBC cholinesterase also assists in predicting the severity of the 
poisoning. Older studies do not confirm the usefulness of pseudocholinesterase 
(CHE) levels in predicting severity (6, 19, 29) but recent studies suggest that CHE 
levels do correlate with severity (26-28). 
 
2.9 Long term effects of AChEI (specifically organophosphates) 
Generally it is observed that, after AChEI poisoning, the acute signs involve 
muscarinic, nicotinic and central neurological effects, as already described. These 
are, however, not the only problems. 
 
An unusual morbidity described is delayed organophosphate encephalopathy where 
deep coma follows a period of consciousness and can be muddled with brain stem 
death except for the miosis seen (56). Patients have recovered and thus this should 
not be muddled with death.  
 
There is unfortunately a risk of late morbidity in survivors of AChEI overdose due to 
respiratory paralysis. This delayed consequence of AChEI (specifically 
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organophosphates) includes the intermediate syndrome of muscle weakness 24-96 
hours following the initial toxidrome (19, 128) and may continue for 4-18 days. There 
is weakness of muscles innervated by cranial nerves, proximal limb weakness and 
neck flexors. Fasciculations seen in the initial crisis are not noted. Supportive care 
(ventilation) may be needed for many days or even weeks. 
 
Chronic nerve damage has been documented starting roughly 2 weeks after 
exposure. This is called organophosphate induced delayed polyneuropathy (128). 
The muscles involved are distal, not proximal, due to damage caused by long tract 
involvement of nerves (88). Recovery is often complete but may persist for years in a 
few cases (25). 
 
Late onset psychiatric disorders (chronic organophosphate induced neuropsychiatric 
disorder) have been recognised (25) but appear to reverse in the long term. In 
chemical warfare attacks post-traumatic stress disorder can persevere for many 
years. 
 
2.10 Conclusion 
AChEI pesticides (most commonly OP and carbamates) are toxic compounds used 
and misused by humanity. They induce a specific toxidrome that can easily be 
recognised by clinicians who are alert to the expected signs and symptoms. Once 
identified, treatment must be initiated rapidly. Despite these interventions, there is 
still risk of death and intermediate or long-term morbidity. 
 
38 
The abuse of AChEI is well documented by people all over the world, but more 
specifically in third world countries in Asia and Africa.  
 
Given this worldwide problem with regards to AChEI abuse, the aim of this report is 
to investigate patients arriving at the Medical Emergency Department of the tertiary 
hospital, Chris Hani Baragwanath Academic Hospital (CHBAH), in Gauteng, South 
Africa with a clinical diagnosis of AChEI overdose in the 6 month period from 1 
August 2013 to 31 January 2014.  
 
The objectives of the study are to describe, in those patients presenting with AChEI 
poisoning: 
 the incidence, age, gender and ethnicity distribution,  
 the temporal relationship in patient presentation, 
 potential or suspected cause of overdose,  
 the toxidrome effects seen, 
 significant blood results, 
 treatment regimens used compared to those suggested in the literature, 
 emergency room outcomes, 
 notification of the disease. 
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3 Methods 
3.1 Ethics 
Ethical clearance for the study was obtained from the Human research ethics 
committee (medical) of the University of Witwatersrand: Appendix 3. Clearance 
Certificate no: M130814. 
 
Ethical clearance was also obtained from the hospital concerned: Chris Hani 
Baragwanath Academic Hospital (CHBAH): Appendix 4. 
 
3.2 Study Design 
This descriptive, retrospective, observational study was conducted at the Chris Hani 
Baragwanath Academic Hospital (CHBAH) Medical Emergency Unit (MEU).  
 
3.3 Study Setting 
CHBAH is a tertiary academic hospital situated in Soweto, south of Johannesburg in 
the province of Gauteng, South Africa. It currently has approximately 2800 beds and 
drains the Soweto (population of 1,271million people) (129) from the southern 
Gauteng area. Gauteng is the smallest province of South Africa but the most 
populous,  with almost 12,3 million people, as per the 2011 census (130).  
 
The MEU of the hospital serves as the emergency department for adult patients (14 
years and older) and sees all emergencies initially, excluding triaged trauma, 
surgical and orthopaedic emergencies. The unit deals with approximately 6000 
patients per month. Patients from the surrounding areas access the unit directly and 
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are also brought in via ambulance. As the MEU is an adult medical emergency unit, 
patients under 14 years were excluded – these patients would have been seen in the 
separate paediatric emergency unit of the hospital.  
 
Patients are also transferred from outlying primary healthcare clinics to CHBAH. The 
MEU thus sees a large volume of patients from the area presenting with known or 
suspected overdose or poisoning. Only those patients who have a history of single 
agent caustic substance ingestion will be triaged directly to surgery and bypass MEU 
at CHBAH. 
 
3.4 Study Population 
The population included all patients whose details were entered in the toxin register. 
These were patients who were suspected, from history and/or clinical signs if no 
history was available, by the medical officer who saw the patient, to have ingested, 
AChEIs between the dates of 1 August 2013 to 31 January 2014. The population 
excluded any patients where the diagnosis may have been missed by the medical 
officers on duty. 
 
3.5 Study Protocol  
3.5.1 Data Collection 
Information for this study has been extracted from the MEU toxin register (Appendix 
1). This register was already available in the MEU prior to the study and was being 
used to identify the types of toxins and/or drugs involved in “overdose” admissions to 
CHBAH MEU. The toxin register consists of a one page tick-list which is filled in by 
the medical officer who initially sees the patient presenting with a suspected 
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overdose. Thus the information obtained was gleaned from history and initial 
examination (clinical parameters) of the patients. The overdose may or may not have 
been confirmed by special investigations by the time the patient left the unit.  
 
The researcher followed up, wherever possible, on patient files following 
documentation found in the register, to fill in any missing information.  
The researcher followed up and traced all documented evidence of blood results 
taken to the hospital laboratory. Where it is documented that results are missing, it 
was only done so after all avenues to find results had been explored. 
The researcher was able to follow up many patients who had had CPR done on 
them. 
 
Evidence of whether notifications were submitted to the relevant South African 
authorities was collected from records kept at the appropriate department of the 
hospital. 
 
3.5.2 Outcome Measures 
The variables that have been collected include patient demographics (gender, age 
and ethnicity), possible cause of overdose (suicide or accidental) and whether the 
patient was pregnant or not.  
The author used the data collected from the history captured in the register, as well 
as follow-up on blood tests documented, for any evidence of use of other drugs or 
toxins ingested by the patient prior to the admission at the time of AChEI intoxication. 
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The time line, including day and month of incident were documented, and type and 
length of exposure (where available) to the poison before arrival in the MEU were 
summarised and analysed. 
Furthermore, clinical variables (signs, symptoms and vital signs) have been studied. 
These include the signs and symptoms of muscarinic, nicotinic and central nervous 
system effects of AChEIs. Blood results, including pH, CO2, bicarbonate, base 
excess, lactate, potassium, white cell count, glucose and pseudocholinesterase 
levels, where available, were collected. For every patient, the researcher followed up 
all documented blood test results at the laboratory. Venous blood gases are usually 
done in the unit for AChEI overdose and those were available on the toxin register.  
 
Management of the patients included in the study, as found in the toxin register, was 
documented. This comprised the need for CPR, endotracheal intubation, adrenaline 
bolus’ and/or infusion, atropine bolus’ and/or infusion, any other drugs used, 
evidence of healthcare provider initiated gastric emptying; or simple observation. 
Information regarding disposal of the patients, either to a high care or Intensive Care 
Unit (ICU) (i.e. a facility with ventilators), a high care monitoring facility (with no 
ventilators) or to the general ward (CHBAH Ward 20), has been documented.  
Data was captured as per Appendix 2 on a Microsoft Excel® document (Microsoft 
Corporation, Redmond, WA, USA) and Microsoft Excel® (Microsoft Corporation, 
Redmond, WA, USA) was used for descriptive statistics.  
In order to insure anonymity Microsoft Excel® (Microsoft Corporation, Redmond, 
WA, USA) (Appendix 3) was used to label each case taken from the toxin register 
separately before data was captured in Appendix 2 for analysis. 
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3.5.3 Data analysis 
The programme, Stata Software TM Version 13, (Stata Corporation, College Station, 
Texas, USA) was used for some data analysis. For descriptive statistics, frequencies 
and percentages were used for categorical data. Significance level where 
appropriate was taken at the 95% confidence interval. 
Data is presented as percentage or total number, and for all cases the denominator 
for n is presumed to be 126 (which is the total number of patients found to have been 
exposed to AChEIs in the period under consideration) unless otherwise stated. 
Using the above methodology, data was captured and analysed as per results 
below. 
 
3.5.4 Funding 
All expenses of paper, printing and traveling were borne by the researcher. 
 
3.5.5 Conflict of Interest 
There is no conflict of interest of the researcher during the time of the study or write 
up of this report. 
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4 Results 
4.1 Demographics 
From the total number of patients exposed to AChEI overdose in the study, 54.3% 
(69) patients were males. Using the proportionality test (Stata Software 
programme®) this is statistically significant within the 95% confidence interval, with a 
p- value of 0.0318. 
 
Figure 4: Age and gender distribution in years of people taking acetylcholinesterase 
inhibitor poisons (AChEI). 
 
Of the 126 patients, 2 were young males admitted unconscious so their respective 
ages were not clarified before leaving the unit – they were presumed to be within the 
21-30 year age bracket.  Of the total group of patients, 23% (29) were less than 21 
years, 45.6% (50) were 21-30 years and 26.2% (33) were 31-40 years. Only 11.1% 
(14) were over 40 years.  
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There was no statistical significance between genders within most specified age 
groups. However there was a statistical significance in the teenage years where 
genders were reversed and females predominated, with p=0.0124. 
 
In terms of ethnicity, as per the South African classification of race, 95.2% (120) 
patients were black (95.2%), 0.8% (1) were Indian and 4% (5) were Coloured. 
 
4.2 Causes of AChEI Overdose 
 
Figure 5: Documented causes of overdose with acetylcholinesterase inhibitors 
(AChEI). 
 
In the study 77% (97) of the patients admitted to attempting suicide. This was 
confirmed by direct questioning of the patient or a family member, or by evidence 
such as a suicide note. All this was documented in the toxin register (Appendix 1). Of 
the remainder, 12% (15) denied suicide and these were classified under accidental. 
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Unknown
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One of these 15 patients took the poison accidentally but it may have been a 
potential homicide case (see section 4.4). The last 11% (14) either refused to divulge 
any information, or could not answer questions regarding what happened due to low 
levels of consciousness and had no surrogate informer in attendance. No homicides 
were documented in this study but potentially a homicide could fall into the 
“unknown” category.  
 
In the study all patients who admitted to taking an AChEI said they took "halipirimi". 
Only 3 patients took a labelled product. Two patients took "Green Leaf" and one took 
"Blue Death". 
 
In this population 97.6% (123) of the patients, on history and/or together with drug 
screening, had single drug/toxin overdose with AChEIs.  
 
Toxic screening was done on 23.5% (29/123) of patients with the single specific 
AChEI overdose history; and found to be negative in all cases. (A toxic screen at 
CHBAH involves blood screening for salicylates, paracetamol, barbiturates and 
benzodiazepines, and is generally not encouraged nor routine practice in the MEU). 
Of the remainder 3.25% (4/123 patients) were tested for paracetamol alone and one 
of these was found to have paracetamol levels in the therapeutic range. In the 90 
patients where no toxic screen nor paracetamol levels were performed, the history 
as taken by the medical officer reflected a single toxin overdose, with no evidence of 
polypharmacy concoctions being involved. 
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The 3 patients who had evidence of multidrug overdose as gathered on history, 
and/or confirmed with drug screening, were 28, 31 and 38 year old males 
respectively. One had neither signs nor symptoms of OP poisoning, was not 
atropinised and was later found to have mildly elevated paracetamol and salicylate 
levels while being observed in the ward. One patient, known to have bipolar disorder, 
had some signs of AChEI overdose but was suspected of having taken opiates and 
benzodiazepines as well. He was atropinised, given naloxone and flumazenil. No 
toxicology diagnosis was confirmed. The third patient admitted to taking paint 
remover and AChEIs, had severe signs of AChEI overdose, was intubated and had a 
CHE of 80U/L. 
 
4.3 Pregnancy 
There were 4 pregnant females in the sample, aged 16 (early pregnancy, exact 
dates not documented), 20 (12 weeks pregnant), 24 (16 weeks pregnant) and 35 
years (20 weeks pregnant). In half these cases the causative trigger of the AChEI 
overdose was attempted suicide due to the unwanted pregnancy. The 35 year old 
patient denied attempted suicide and said the symptoms started after she ate 
porridge; in the other case the cause of the overdose was not established. Two 
patients had mild symptoms and signs of OP poisoning but 2 were severe, both of 
whom required intubation and ventilation. All exhibited miosis. In only one case was 
the CHE level tested – the result was 204 U/L (extremely low). All patients had 
aggressive atropinisation. None of these patients died in MEU. No patients 
experienced abortions in MEU. The 35 year old went home, stable, the following day. 
No long-term follow up was conducted to track the pregnancies in any of the 4 
cases. 
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4.4 Type of exposure 
All patients with documented exposures (via history and/or pseudocholinesterase 
level results) to AChEI (89% or 112 patients) admitted or suspected it to have been 
ingested orally.  No exposures were noted from spraying of farm pesticides. There 
were no group exposures to inhalational gases producing an AChEI-like toxidrome 
during the study period. One family group exposure was recorded where a senior 
member of the family allegedly deliberately sprinkled AChEIs over potato chips 
which resulted in a total of 5 people being affected (3 of these were children and thus 
not seen in our unit). This is an example of a potential homicide case. 
 
4.5 Timing of presentation 
 
Figure 6: Percentage of patients presenting within certain time periods from time of 
overdose 
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Unfortunately, the majority of records (41%) did not show documented time from 
poisoning to arrival at hospital. Most poisoned patients where timing was recorded 
(58% (74) of total records) presented within 24 hours of overdose. Of the total 
records where timing was indeed recorded, only 0.8% (1 patient) presented after 24 
hours. Although 12% (15) of patients (for whom timing data was recorded) arrived 
less than 2 hours after ingestion, only 1 patient received activated charcoal. 
 
4.6 Temporal Distribution 
 
Figure 7: Percentage of patient ingesting acetylcholinesterase inhibitors (AChEI) per 
month over the 6 month period 
 
More patients took AChEI overdoses in December than in other months. It is noted 
that there was double the number of overdoses in December compared to August. 
However, there was no statistical significance between the months at the 95% 
confidence interval as per the Fisher exact test calculated on Stata® (p=0.623). 
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Figure 8: Percentage of patients taking acetylcholinesterase inhibitors (AChEI) per 
day of the week in the 6 month period. 
 
There were more weekday overdoses (Monday-Thursday) recorded than overdoses 
over weekends (Friday to Sunday) with Wednesday having the most patients 
presenting with AChEI overdose: 17.5% (22). There were 26 Wednesdays in the 
study period which is the same number as Saturdays, Sundays, Mondays and 
Tuesdays. There were 27 Thursdays and Fridays during the period. Only 3.2% (4) of 
patients presented with AChEI overdose on a public holiday. (There were 6 public 
holidays in the 6 month period studied and there are 12 public holidays on the South 
African yearly calendar). However, there was no statistical significance between the 
days at the 95% confidence interval as per the Fisher exact test calculated on Stata 
® (p=0.460). 
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4.7 Signs and Symptoms 
4.7.1 Signs of poisoning 
 
Figure 9: Graphic representation of signs related to acetylcholinesterase inhibitor 
overdose observed in the patient population 
 
At initial presentation muscarinic signs and fasciculations were most evident as 
reflected in Figure 9. Miosis was the most common and easily recognizable sign 
noted (73.8%), followed by vomiting (54.7%) and respiratory secretions (49.2%). 
These are muscarinic signs of overdose. Fasciculations – noted in 48.4% of patients 
– are a nicotinic sign. Weakness (1.6%), an important nicotinic sign because of the 
danger of respiratory failure, was not frequently apparent initially, or alternatively, not 
well documented. Only 3 patients had seizures or a history of seizures before arrival. 
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A fifth of the patients presented with coma (GCS below 9) while 8.7% (11 patients) 
had no signs of AChEI overdose despite a history claiming overdose. 
 
4.7.2 Glasgow Coma Scale 
 
Figure 10: Glasgow Coma Scale (GCS) at initial assessment of patients.  
(* indicates a patient who arrived intubated and whose GCS was not documented 
prior to intubation) 
 
Of the total number of patients analysed, 15% (19 patients) had a GCS of < 9 on 
arrival and required intubation to maintain and protect their airways. All of these 
patients also had low pH (i.e. were acidotic). A total of 29% (37 patients) were 
intubated: 7 prior to arrival (intubated by EMS or by the doctor at the clinic) and 30 
during the time in MEU. Thus, in 11 patients, the decision to intubate was not based 
0
10
20
30
40
50
60
P
e
rc
e
n
ta
g
e
 o
f 
p
a
ti
e
n
ts
 
Glasgow Coma Scale (GCS) 
Glasgow Coma Scale of patients at presentation 
53 
on GCS at all. One of these patients, who came in with a GCS of 15, had a 
convulsion and was intubated thereafter. The remainder were intubated while 
undergoing observation in the MEU and found to be deteriorating due to weakness 
and respiratory compromise.  
 
4.7.3 Pulse rate 
 
Figure 11: Initial pulse recorded at time of patient presentation in the Emergency Unit 
 
Initial pulse was documented on 91.35% (115) patients. Of the total, 8.7% (11) had 
no pulse on arrival and CPR was initiated. Severe bradycardia (heart rate < 50/min) 
was documented in only 9.6% (11/115) of patients with a pulse. A pulse from 50 to 
59/min was documented in 8.7% (10/115) of patients. Of those with a pulse over 
100/min (16.5% or 19/115 patients), one had received atropine, 15mg, at the clinic 
before referral; and one had a concomitant right middle lobe pneumonia. 
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4.7.4 Blood pressure 
 
Figure 12: Initial systolic blood pressure recorded at time of patient presentation in 
the Emergency Unit 
 
Of the 82.5% (104) of patients with documented initial blood pressure readings, 8% 
(10/104) had hypotension (systolic blood pressure below 100mmHg).  
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4.7.5 Respiratory rate 
 
Figure 13: Initial respiratory rate recorded at time of patient presentation in the 
Emergency Unit. 
 
Of the 93 patients whose respiratory rate was recorded (74% of patients), 27% 
(26/93) had a rate of above the normal upper limit of 20 breaths per minute for 
adults. With regards to the respiratory system, respiratory secretions were noted in 
49.2% of patients (See Figure 9). This is an important sign to note as the initial 
anticholinergic (antimuscarinic) management is based on this finding.  (Repeated 
atropine dosing is based on the persistence of respiratory secretions; Chapter 1.9). 
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4.8 Blood results 
The following blood results, where available, were analysed: potassium, lactate, 
white cell count, glucose, pseudocholinesterase levels and venous blood gas.  
 
4.8.1 Potassium 
 
Figure 14: Initial blood potassium results 
 
Potassium results were documented in 123 patients: 55% (68/123) had low 
potassium of <3.5mmol/l of which almost half (26% (32/123)) were below 3mmol/l. 
One patient had slightly raised potassium of 5.8mmol/l which was documented 
during CPR and the patient’s pH was 6.71, so corrected for the pH it would have 
been normal to low. 
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4.8.2 Lactate 
 
Figure 15: Initial blood lactate results 
 
Lactate results were recorded in 89% (112 patients). Of these, 40.2% (45/112) were 
within a range for normal perfusion (lactate <2.5mmol/l), 34.8% ranged from 2.5-
5mmol/l and 21.4% (24/112) were very high at 5.1-10mmol/l. A small percentage, 
3.6% (4/112) of patients, had a lactate above 10mmol/l.  
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4.8.3 White Cell Count 
 
Figure 16: Initial Blood White Cell Count 
 
White cell count (WCC) was documented in 80% (101) of patients. Of these, 39.6% 
(40/101) had a normal WCC (4-10.1x109cells/l), 50.5% (51/101) had a WCC 
between 10.2 and 20x109/l and 11.9% (12/101) had a WCC above 20x109/l.  
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4.8.4 Glucose 
 
Figure 17: Initial blood glucose levels 
 
Glucose levels were recorded in 92% (116) patients.  Of these, 16.4% (19/116) had 
normal glucose levels of 4-6mmol/l. Only 3 patients had slightly low glucose 
(3mmol/l, 3.7mmol/l and 3.9mmol/l). 33.6% (39/116) had glucose between 6.1 and 
10mmol/l; 39.7% (46/116) had glucose between 10 and 20mmol/l and 7.8% (9/116) 
had glucose above 20mmol/l. No patient in this study was documented to have 
diabetes mellitus. 
 
If these patients had been in a critical care setting then an acceptable range of 
glucose may be considered to be 4.5-10.1mmol/l (conventional glucose control) 
(131) which would include 49.1% of those patients whose glucose was documented. 
Below 4.5mmol/l there is a risk of hypoglycaemia. Hypoglycaemia can be considered 
if the glucose is < 4.0mmol/l (132). Critical care monitoring involves control of the 
glucose in a high-care setting. In this cross-sectional study only initial glucose was 
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recorded for each patient. No treatment plan for glucose control was initiated for an 
initial random glucose level after AChEI overdose. This would be considered after 
initial stabilization and conventional AChEI treatment has taken place. 
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4.8.5 Pseudocholinesterase 
 
Figure 18: Blood pseudocholinesterase results 
 
Pseudocholinesterase levels (CHE) were only done on 52% (65/126) of patients. Of 
these, 38% (25/65) had extremely low CHE (<200units/litre); 41.5% (27/65) had very 
low CHE levels (200-2000units/litre); 6.2% (4/65) had slightly low levels (2001-
3899units/litre) and 13.8% (9/65) had normal CHE (>3930units/litre in females or 
4620units/litre in males). 
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4.8.6 pH 
 
Figure 19: Initial Blood pH in patients presenting with acetylcholinesterase inhibitor 
overdose. 
Of the 113 patients in the study who had venous blood gases documented in the 
toxin register the majority (56%) were acidotic.  
 
All patients (30) who were intubated in MEU were acidotic except three. One had a 
normal blood gas initially but deteriorated later resulting in a decision to intubate. In 
this case a second blood gas was not documented. The other one was a patient who 
came in with a normal blood gas then had a seizure and was intubated thereafter: 
once again a second blood gas was not documented. In the third patient the pH was 
normal and no reason was given for intubation. Of the remaining 27 patients 
intubated in MEU, 12 had pH less than 7.11 and all patients with a pH less than 7.11 
were intubated.  
 
15% 
29% 
56% 
Initial blood pH 
pH > 7.44,  Alkalaemia
pH 7.36 - 7.44,  Normal
pH < 7.35,  Acidaemia
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4.9 Electrocardiogram (ECG) analysis 
ECG analysis was not performed in this study as copies of ECGs were not required 
or recorded in the toxin register. However, in one ECG that was included, the ECG 
was significant. The patient – a 36 year old male found unconscious at home – was 
brought in with typical AChEI signs, and was hypothermic (unfortunately the patient 
was documented to be “cold” but the temperature was not documented in the toxin 
register). Following atropine administration, the ECG (recorded after initial 
stabilization) revealed the Osborn waves compatible with hypothermia (best seen in 
leads V4-V5, and also in leads II, III and aVF), as well as an atrial fibrillation with an 
approximate rate of 102 beats/minute. See Figure 20 below.  
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Figure 20: ECG of 36 year old male brought in, very cold and with signs and symptoms of AChEI overdose. 
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4.10 Management 
Generally in this study early decontamination (wash down) was not practised as 
patients presented with ingested poisoning and not dermal exposure nor inhalational 
poisoning. Oro-gastric tubes were inserted only if the patient was intubated, in order 
to decompress the stomach as per standard practice in the unit for intubated 
patients. Patients were washed and cleaned with soap and water before going to the 
wards due to the contamination of body and clothes with faeces, urine and vomitus. 
 
During the study only one patient was given activated charcoal as the patient was 
bought in stable (GCS of 15 and no signs of AChEI overdose) with a history of taking 
the AChEI overdose only minutes before arrival in the hospital. This procedure was 
done at the insistence of the doctor who was to take over management of the patient 
in the ward.  
 
Figure 21: Method of atropine dosing per percentage of patients treated. 
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In 90% of cases atropine was administered. The remaining 10% of patients received 
no atropine treatment as they had neither signs nor symptoms of AChEI overdose.  
 
As can be seen in the graph the majority of patients who received atropine were 
given one or more bolus’ first, (39% had a single bolus to control secretions and 36% 
needed more than one dose to control secretions) and then the infusion was 
initiated. In 5% of cases the dose of atropine was not documented. 
 
Of the remaining 10% of total patients 2% had only one bolus dose of atropine and 
no infusion; and 8% only received an infusion (no bolus). Most of these patients 
presented with minimal signs of overdose or a history of overdose but no signs. This 
possibly reflects uncertainty about the diagnosis at the time of presentation. Test 
dosing was not done (as described in 2.7.2.2). One of the patients who only received 
a single bolus died during CPR so there was never time to consider an infusion. One 
of the patients who received an infusion only had already been treated at the clinic. A 
single patient who had received only an infusion deteriorated 9 hours later and 
required intubation in the acute care ward. 
 
Neither glycopyrrolate nor oximes were administered to patients while they were in 
the unit. There were no patients given ancillary or experimental medication such as 
magnesium sulphate, sodium bicarbonate, fresh frozen plasma, salbutamol, 
ipratropium bromide nor haemodialysis while in the unit. 
 
Benzodiazepine use was poorly documented in the toxin register as were the drugs 
used for intubation thus analysis of these drugs was not possible. 
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Urgent symptomatic treatment included intubation and ventilation – these 
interventions were initiated on clinical grounds, usually for multiple reasons such as 
hypoxia (low saturation) (2 patients), low GCS (5 patients), a patient who had a 
seizure (1 patient), poor ventilation (high pCO2), (10 patients), severe weakness 
(patient unable to lift his or her head or poor hand grip) (2 patients) or during the 
period around CPR in the unit (10 patients).  A further seven patients, considered 
critically ill, were intubated either on scene or at the fire station by emergency 
medical services personnel, or by doctors at the clinics, prior to transport to the unit. 
A total of 29% (37 patients) were intubated of which 19% (7/37) were intubated 
before arrival at the hospital. Three of the intubated patients were documented to be 
given suxamethonium for intubation. 
 
Patients with severe acidosis as seen on venous blood gas were treated with 
ventilation and fluid support, as noted under blood gas pH analysis (4.8.5).  
 
Cardiopulmonary resuscitation (CPR) was done on 8.7% (11) patients with AChEI 
overdose while they were in the MEU. (During this study no patient was transported 
in with CPR in progress, either by family or emergency services). Three of the 
patients who had CPR had it twice: one had CPR at the clinic and again on arrival in 
MEU after a seizure; and 2 had CPR twice in MEU. Four were documented to have 
pulseless electrical activity (PEA) at the time of starting CPR, while one was 
documented to have asystole which then converted to a ventricular tachycardia then 
PEA before returning to spontaneous circulation. Of those patients who underwent 
CPR, 72.7% (8 patients) were noted to have miosis at time of presentation.  
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A total of 3 patients died in MEU (2.4%). The 2 patients who had CPR twice never 
recovered after the second arrest and only one patient never achieved return of 
spontaneous circulation during the first attempt at CPR.  
 
Of the 8 patients who had CPR and were transferred out of the unit, 4 were lost to 
follow up, 2 died 24 hours later and 2 had severe neurological deficit after 24 hours 
with very little chance of recovery. This bring up the mortality to at least 4% (5 
patients confirmed to have died) and probably higher given that there was little 
chance of recovery of at least another 2 patients. 
 
4.11 Disposal 
 
Figure 22: Patient disposal once initial stabilization done 
 
Two thirds of patients (66% (83), once stabilized, were sufficiently stable to receive 
ongoing management in an acute care ward without ventilation but with continuous 
Patient disposal 
ICU
High Care (with ventilators)
Acute Care (no ventilators; full
monitoring)
Ward (limited monitoring facilities)
Patient Refused treatment
Died in MEU
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monitoring. Those who required ventilation (19% (24) were referred to the 
appropriate wards where ventilators and staff were available to continue critical care. 
Only 12% (15) of patients went to a standard ward with limited monitoring facilities. 
Of these, a third (10) of patients did not have signs and symptoms of AChEI 
overdose while in MEU, 4 had mild signs and 1, who with a poor prognosis following 
CPR, was not allocated a ventilated bed outside MEU due to resource constraints. 
One patient refused treatment and left the hospital while 2.4% (3) of patients were 
declared dead in the unit following unsuccessful resuscitation attempts. 
 
4.12 Notifications 
Data obtained from the nursing services department that collects and correlates the 
notification forms and sends the information to the authorities shows that only 3 
cases of pesticide poisoning were notified in whole of 2013, and a total of 25 cases 
were notified in 2014. In this study of 126 patients seen with AChEI overdose in a 6 
month period, 22 were seen in Jan 2014 and the remainder seen in the last 5 
months of 2013. Thus notifications for this problem were not taken seriously during 
this time, and in general the staff were non- compliant with this policy. 
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5 Discussion 
5.1 Demographics 
At the tertiary hospital where this study was conducted there was a statistically 
significant predominance of males over females (p value = 0.0318 as discussed in 
Chapter 4.1) presenting with AChEI overdose. This correlates with many studies 
from India, Taiwan and South Africa (36, 39, 41, 42, 45, 49, 57) showing that men 
tend to overdose on AChEI more commonly than women. See Section 2.5.2 for 
details. 
 
However, other studies (as reflected in the literature review) found that more females 
overdosed on AChEIs than males. This was reflected in this study in the teenage 
years where female overdosing predominated (p value = 0.0124 as discussed in 
Chapter 4.1). This correlates well with the study in Tshwane (49) where, although 
male predominated overall, females in the under 30 age group were “significantly 
affected”. 
 
Most overdoses occurred in the younger age groups with only 11.1% of the study 
population overdosing being over 40 years. This finding was comparable to most 
studies accessed: Zimbabwe (33), India (36, 37, 41), and Nepal (40). 
 
By far the majority of patients who exhibited the toxidrome in the CHBAH study were 
black. This is congruent with the population ethnicity of the community served by 
CHBAH (greater Soweto and Southern Gauteng community) (129).  
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Table 3: Greater Soweto population ethnicity compared to ethnicity of patients with 
AChEI toxidrome (adapted from data correlated by Adrian Firth, Census 2011) (129). 
Population group People Percentage Toxidrome 
Black African 1253037 98.54% 95.2% 
Coloured 13079 1.03% 4% 
Other 2674 0.21% 0% 
White 1421 0.11% 0% 
Indian or Asian 1418 0.11% 0.8% 
 
Further studies would be needed to generalise the findings in South Africa and 
Gauteng to understand whether people of other ethnicities overdose with AChEI and 
pesticides in general, or rather use other methods of overdose, including prescription 
drugs. Previous small studies from hospitals in Durban (46), Johannesburg (47) and 
the mortuary in Pretoria (48) have found that people from other ethnic groups prefer 
to use other drugs to overdose or attempt suicide rather than AChEI. 
 
5.2 Cause 
From the histories taken in the study population, suicide attempt was the 
predominant cause of AChEI overdose (77%); 11% of patients would not or could 
not disclose the cause. As noted in section 2.4 this is in keeping with most studies in 
third world countries where there is a firm predominance of suicidal intent, ranging 
from 55,8% in the Western Pacific islands, to 98,6% in one of the Indian studies. It is 
interesting to note that in the new study from Tshwane, South Africa (49) that they 
found only 51,7% of cases were related to attempted suicide. 
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The remaining 12% of people poisoned denied suicide and most were unable to say 
exactly how the overdose happened. These patients admitted that the symptoms 
occurred after ingestion of food or liquids. None of the patients came from an 
agricultural milieu. It is unclear from the histories elicited whether or not patients felt 
there was foul play (attempted homicide), or whether their family or colleagues may 
have been experimenting with various available drugs. The exception was in the 
family overdose case where there was suspicion of foul play as discussed in Chapter 
4.2 and 4.4. There were occasions involving teenagers presenting from schools 
where they (and/or the escort) were adamant that the problem only started after 
drinking/eating something received from peers at school on that day.  
 
The incidents of alleged overdose of school-going teenagers is concerning as the 
source of the AChEI is not clear. It is known in the community that drug dealers and 
users mix drugs and patients admit to taking heroin and halipirimi as a mixture, and 
that Nyaope1 may contain “halipirimi/rat poison” as part of the concoction (133). (This 
has also been communicated from patients to the author). Either way, the results are 
dangerous and potentially deadly for the teenage recipient. 
 
There were no incidents where many people came in at the same time from one 
area which may have suggested contamination of food or fluids in a public health 
environment; or aerosol contamination from agricultural spraying.  
  
The causes of overdose compares well with documented studies on AChEI 
poisoning elsewhere in the world as referenced in Chapter 2.4.1 where most of the 
                                                          
1
 Nyaope is a local mixture of drugs including but not limited to heroin, dagga, AChEI, Anti-Retroviral Drugs and 
anything else that local drug dealers may add. 
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pesticide and AChEI overdoses were in patients who attempted suicide  (31, 36, 37, 
39, 40). 
 
5.3 Mortality 
As found in the literature, and as expected from a poisonous substance, deaths 
occur after AChEI overdose. In this study which only reflects the acute care and 
management of all patients poisoned by AChEIs within a six month period in the 
Emergency Department, 3 deaths (2.4%) were recorded in the unit.  
Internationally the death rates was documented at 15% (6) and in individual studies 
rates ranged from 5.6%-27% (33, 43, 44) as referenced in Section 2.5. This study’s 
lower death rate could possibly be because the poison ingested is slightly less toxic 
or taken in smaller doses than some of those AChEI accessed in other parts of the 
world. It could also be because access to a hospital or healthcare facility is easier 
and quicker in this urban setting. The final death rate from patients in this study over 
time was definitely higher as it is known that 2 patients who had CPR died 24 hours 
later. Other patients with severe intoxication or brain damage were not followed up in 
the wards to confirm final outcome. 
It should be noted that some of the very high death rates in the literature were 
described within high care and ICU settings (51.2% in one study) where the patients 
were already triaged as the severe cases of AChEI overdose, so those statistics 
reflect a subsection of people poisoned. 
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5.4 Pregnancy 
Healthcare professionals should be aware of the need for vigilance when treating 
pregnant women due to potential for drug interactions and teratogenicity in the 
foetus. The literature does not have large randomised controlled trials on pregnant 
women who overdose on AChEIs. However it is clear, even from this small study (4 
females in the study were pregnant) and other small case studies in the literature 
(62) that women who are pregnant do try to commit suicide by use of AChEIs, or are 
at risk from AChEI overdose from other causes (63). Fortunately the initial 
management of AChEI overdose involves supportive treatment and atropine which 
has not been shown to be dangerous to the foetus.  
 
5.5 OP vs Carbamates 
Organophosphates and carbamates are sub-categories of AChEI. As discussed in 
Chapter 1.3 the different structures may not influence the toxidrome but do influence 
the breakdown of the poison in the body of the victim and thus influence the antidote. 
Unfortunately all but 3 patients that presented in this study had taken the “halipirimi” 
as shown in Figure 3 or did not say or know what had been taken. All of the 3 
patients who used labelled AChEIs had no signs and symptoms of poisoning and 
only required admission for observation to the general medical ward. One of these 
patients refused to be admitted and left the hospital.  
 
The labelled pesticide products used were “Green Leaf” (in 2 cases) containing an 
OP (acephate); and “Blue Death” (1 case) containing a carbamate (carbaryl). The 
labelled products are toxic, but possibly less so than the unlabelled products. If a 
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product is labelled it is possible to source information for exact treatment. There are 
legal requirements to label toxic products in South Africa (20, 51). At the tertiary 
hospital where this study was conducted, information for poison treatment is 
accessed from “Afritox”®, the poison website run jointly by the University of Cape 
Town and Stellenbosch for the South African medical community. As a healthcare 
professional observing a toxidrome of AChEI overdose when an unlabelled or 
unknown product was used, the immediate treatment protocol becomes limited to 
symptomatic treatment and atropine – oximes are not given. As mentioned in 
Chapter 1.9 oximes are not available on tender in state hospitals and it is difficult to 
motivate for them based on the large volume of patients who overdose on unlabelled 
products, which could, in fact, be carbamates, as noted in the Pretoria mortuary 
study (48). 
 
5.6 Temporal distribution of overdosing (Day and month) 
More overdoses occurred in December compared to any other month although this 
was not statistically significant as noted in Chapter 4.6 (p=0.623). It may be expected 
that more overdoses occur during holiday and exam results season (which occurs 
from early December to early January in South Africa) but, as it was not statistically 
significant in this study, this would have to be monitored over a few years to better 
identify any trend. The winter months in India (59) were found to be a more common 
time for overdosing than summer, and February and August were more common 
months (36) which is different to this study’s results. 
 
The daily distribution of overdosing was unexpected as mid-week overdoses were 
more common (notably on a Wednesday), but not statistically significant (p=0.460). 
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This is the opposite to what was found in India where weekends were more 
commonly associated with AChEI overdose (59). The author can find no reasonable 
explanation for this as one might have expected there to be a larger volume of 
overdoses on a weekend, or before, or during a public holiday. This was not the 
case. Also, there was no specific incidence of large numbers of overdoses occurring 
around a specific time. 
 
5.7 Cholinesterases 
In this study pseudocholinesterase (CHE) results were available to confirm diagnosis 
in just over 50% of cases. Of these, 86% were below normal and 38% of results 
were extremely low. In studies from India up to 77% of CHE results were below 
normal (59). In India it has been shown that lower CHE levels correlate with severity 
of presentation. In this study using a binary logistic regression test there was no 
correlation between CHE levels and severity (p=0.294; odds ratio 1.0; 95% 
confidence interval (0.08-0.68)). This may be true or it may be because the doctors 
may have been more likely to take CHE levels when there was more doubt about the 
diagnosis (i.e. in the patients with fewer or minimal signs of toxicity), and they did not 
worry to test CHE levels in severe cases where they considered the diagnosis 
obvious. 
5.8 Toxidrome effects 
In this study careful observation was made of the signs observed by the treating 
doctor. Muscarinic signs (the cholinergic crisis) are usually very obvious and this is 
confirmed in this study. 
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The most noticeable sign is miosis with 74% of patients exhibiting this feature.  This 
makes it a useful and important sign to assess while trying to make a quick diagnosis 
in a patient presenting with sudden onset of abdominal pain, vomiting and diarrhoea 
in the Emergency Department. In other studies miosis was also noted to be 
prominent (58, 72, 73). Miosis is also prevalent in those patients presenting with no 
pulse (72.7% of those requiring CPR in this study had miosis). This observation is 
very useful in guiding the treating physician to start immediate anticholinergic 
treatment as per advanced life support principles to treat the cause of the cardiac 
arrest. Miosis has also been documented as a “stronger indicator” of AChEI 
overdose by other authors (74). 
 
Respiratory secretions, another muscarinic effect, were observed in 49.2% of 
patients. This common sign is also noted in other studies (58, 72, 73) and is useful to 
observe as the initial anticholinergic management is based on this information.  
 
Other muscarinic signs identified are probably more nebulous, as patients presenting 
with many other conditions may exhibit these signs (e.g. vomiting and diarrhoea). 
 
Sweating, which was noted in this study at 31.7% of patients, is often associated 
with sympathetic over-activity from other conditions, but can be very noticeable in 
AChEI overdosing as, until controlled, no electrodes stick to the chest wall and thus 
ECG monitoring can become impossible until the muscarinic signs are somewhat 
controlled. 
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Of the nicotinic effects seen in this study fasciculations were commonly noted in 48% 
of patients involving all muscles while weakness was only noted in 1.5% of patients. 
This low observation of weakness was also documented in the literature review. 
Since muscle weakness translates into inadequate ventilation, it is an important 
finding and a potential cause of death. If patients are genuinely not weak that is a 
good sign, but if the sign is missed then there is a real risk of mortality. This lack of 
observation could reflect inadequate knowledge on how to actually test for clinical 
weakness and document it, rather than a lack of genuine weakness.  
 
Acute central nervous system effects of AChEI overdose in the population studied 
were mainly limited to coma, confusion and a few patients with seizures. Seizure rate 
was comparable (2.4%) to other studies (58, 73) where a 1.8%-10.6% seizure rate 
was found. Seizure activity may be related to the type of poison used (OP nerve 
gases such as tabun and soman appear to have more propensity for seizure activity) 
(74). Well oxygenated patients may also have less chance of seizure activity (74).  
 
5.9 Blood results  
Blood results reflected upon are potassium changes, pH, lactate and those changes 
associated with a stress response (white cell count and glucose). It should be noted 
that, at CHBAH MEU, venous blood gases are used in the emergency resuscitation 
of AChEI overdoses. 
 
Hypokalaemia was well documented in this study with 55% of patients having 
potassium below 3,5mmol/l. This is consistent with other studies (25, 28, 72) and 
congruent with fluid shifts from vomiting, diarrhoea and diaphoresis. Potential 
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hypokalaemia needs to be emphasized as replacement needs to be considered in all 
cases of AChEI poisoning. 
 
Lactate increases are to be expected due to under-perfusion following the acute 
cholinergic crisis, fluid loss and resultant hypotension. Recent studies confirm high 
lactate as a predictor of severity with higher lactates indicating a possible higher 
mortality as well as morbidity (82, 83). In this study 59.8% of patients had a raised 
lactate of > 2.49mmol/l with 3.6% having a lactate above 10mmol/l. Using the binary 
logistic regression test there was a correlation between increasing lactate levels and 
severity, (p=0.000; odds ratio of 1.622 at a 95% confidence interval (01.00-1.01)). 
 
Glucose and white cell count are grouped together as stress response markers. Both 
were raised in most patients in the acute setting. These are in patients without sepsis 
or diabetes; it needs to be emphasised that these blood tests should be read in 
association with the clinical condition. These results are comparable with other 
literature findings (58, 71, 80, 81). 
 
5.10 ECGs 
Only one ECG was available for analysis in this study. It showed atrial fibrillation 
which has been documented in the literature. However, Osborn waves of 
hypothermia, which were noted on this ECG, could not be found documented in 
other literature on AChEI overdose. Although temperatures were not documented in 
this study hypothermia can be expected due to evaporative losses following 
sweating from muscarinic over-activity, delayed presentation of patients to the 
hospital and ambient temperatures being lower than human body temperature. 
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There is also the possibility that the poison may directly affect the body temperature 
regulation, initially causing hypothermia (77). 
 
5.11 Decontamination 
In the acute setting for individual cases of AChEI overdose, such as seen with 
suicides and most accidental poisoning as in this study, most evidence is against the 
use of gastric lavage, use of ipecacuanha for induced emesis, or the use of activated 
charcoal as discussed in Chapter 2.6.1. It is safer to start with immediate treatment 
with oxygen, atropine and other agents if available and stabilise the patient, than risk 
aspiration with initial attempts to empty the stomach contents.  
 
As discussed in Chapter 4.10 patients who presented with AChEI overdose did not 
undergo gastric lavage, and were washed with soap and water and clothing removed 
after initial stabilization. Staff used standard personal protective gear, namely gloves 
and protective shoes, to wash down patients. In our unit protective goggles are not 
used for patients with para-suicidal orally ingested AChEI overdoses, which is 
different to first world countries where full PPE maybe used; but not different to other 
third world countries where often only basic self-protective clothing is available (90) . 
Oro-gastric tubes were only inserted after intubation as is standard practice with any 
intubated patient in the unit.  Only one case had activated charcoal given.  
 
5.12 Management 
In the acute setting symptomatic treatment and urgent anti-muscarinic medication is 
required. 
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In our unit the study shows that the regimen of high dose and escalating atropine as 
needed to dry secretions, followed by an infusion, is most often used. Three quarters 
(75%) of patients treated initially received this regimen. This practice of escalating 
atropinisation follows the current recommendation (6, 16, 38, 86, 109). Other acute 
management was not well documented in the reports used for this study. 
 
Benzodiazepines have not been used routinely in our unit for AChEI overdoses as 
was borne out in the study and there was no documentation of their use in the 
patient toxin register. (Generally midazolam would be used for post intubation 
sedation, and lorazepam or clonazepam would be used to control seizures). 
Diazepam is well described for use in AChEI overdose and appears to limit long-term 
neuromuscular complications, but the literature does not clearly define at what point 
it should be used. In this study 70% of patients were not intubated and 70% of 
patients had a GCS greater than 10. Doctors would have been reluctant to give 
benzodiazepines to the more stable patients such as those mentioned above. Only 
two patients were documented to have seizures and the specific management or 
control of the seizure was not documented. 
 
5.13 Notifications 
It is clear that notifications of pesticide poisoning have not been adequately 
managed at the hospital during this time. In this study it is unlikely to be due to under 
diagnosis of the poisoning as a possible cause of lack of notification as compared to 
a Cape Town study (20). There needs to be more emphasis on highlighting the need 
to do this for all healthcare practitioners involved in these patients.  This may also be 
needed at a student level where forensic and infectious disease education of nurses 
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and doctors may not stress the importance of notifications for the benefit of the 
community. It is the opinion of the researcher that there is a lot of disregard amongst 
staff in the Emergency unit to notify cases and it is considered to be another unit’s 
job. In some cases this may be due to a stressed workload and time constraints. 
There is no consequence to staff if a case is not notified despite there being a legal 
obligation to do so.  
It has been noted that the system is passive and paper-based (49) so there is 
potential for loss of information anywhere along the chain from patient diagnosis to 
local authority notification. 
Apart from the disregard of the legal requirement of healthcare practitioners to notify, 
this is potentially the first step in advocating for authorities to become aware of the 
problem and start to remove illegal pesticides from the streets of our province and 
country. A new study from Tshwane, Gauteng also highlights this problem (49). More 
robust and accountable mechanisms should be instituted to co-ordinate and enforce 
the notification process. These illegally available pesticides are the bulk of the 
accessed AChEI used for poisoning.  
 
5.14 Limitations of Study 
Limitations of the study, including those already mentioned, include lack of data 
being filled in on the toxin register (e.g. as noted in very few records where the time 
of overdose was only noted in 41% of registers and/or patient files in section 4.5); or 
incomplete data being recorded (e.g. “atropine given” but no dose documented). 
Also, even if completed fully, the toxin register might not have had enough 
information to answer all questions. Follow up of many files was done in the 24 hours 
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post incident but records/files were still incomplete in certain cases and there was no 
more detail in the file than in the register. A few files were lost and thus inaccessible. 
At the tertiary hospital in 2013 it was common practice for patients to take their files 
home so records were not always available for review. 
 
Medical officers may have been inaccurate in their initial assessment of the toxin 
overdose so results could be exaggerated (e.g. patient with sweating and vomiting 
could be assessed as OP overdose when there was another diagnosis) or under 
reported (e.g. a patient with vomiting and diarrhoea was diagnosed with 
gastroenteritis, and the overdose missed).  
 
Sometimes blood tests were not performed, or done and not recorded, but other 
times blood tests were done but clotted (which was picked up when results had to be 
accessed from the laboratory computer in the hospital), or were lost in transit so 
results could not be traced. Pseudocholinesterase levels were done because this 
test can be done at the hospital, while red blood cell cholinesterase levels were not 
done as this test is not available at the hospital. 
 
As the study is a cross-sectional study, follow-up in the wards was not conducted, 
thus there can be no discussion on further outcome of patients, nor ongoing 
treatment. This has resulted in some important outcomes possibly being 
underreported, notably the mortality. There is evidence that many of the patients who 
had CPR died or probably died in the wards, which would increase the mortality of 
this toxin. Long-term sequelae were not investigated as a result of the cross-
sectional study.  
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6 Conclusion 
In this descriptive cross-sectional study I have looked at the occurrence of AChEI 
overdosing in an urban tertiary hospital in Gauteng, South Africa. In most cases it 
appears that the poisoning is deliberately ingested with suicidal intent, as is 
commonly seen in other third world countries. The toxin is typically obtained from 
vendors who sell the AChEI pesticides illegally on the streets.  
 
The evidence shows that the young, healthy, potentially economically active 
population abuses these pesticides, akin to other third world communities. These 
people are seldom the chronically ill and very few are mixing the AChEIs with other 
poisons or drugs, and it is an unnecessary tragedy when life is lost. 
 
The initial treatment in this study involves use of the antimuscarinic drug, atropine, 
and supportive management. The small numbers of early deaths in the unit are 
directly related to death from the pesticide as all deaths followed CPR in an initial 
attempt to reverse the severe effects of the poison after the patient arrived in the 
unit. It is unlikely that additional use of oximes and benzodiazepines at this point 
would have reversed the mortality. 
 
More information could be obtained from a longitudinal study designed to follow up 
patients in the wards. Follow- up for further fatalities could then be obtained. Oximes 
and other experimental drugs or theories could be tested for their feasibility and 
economic viability by designing and running a double-blind prospective trial.  
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It would be interesting for researchers to follow up pregnant patients who overdose 
on AChEI to highlight demographics of this specific population. Also there is a need 
to confirm if there are long term consequences to the foetus’ or not, and if 
progesterone is really needed as postulated. It is also interesting to note that newer 
studies are investigating predictive markers for severity and this theme could be 
explored further. 
 
Further prospective investigations could be done to confirm or refute evidence that 
other treatments such as use of magnesium sulphate, bicarbonate, rocuronium, lipid 
emulsion or fresh frozen plasma would help patient improve morbidity or long term 
mortality. 
 
Overall, however, much of the problem of AChEI overdose is probably preventable in 
Gauteng, South Africa if the sale of illegal AChEI could be curtailed. 
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8 Appendices 
8.1 Appendix 1 
 
Date:
Study number Gender M□       F□
Ethnicity Black □      White□    Indian□ Coloured□    Other□ Age
NHSL reference 
number(bloods) or 
sticker
Drugs taken Paracetamol□     Organophosphates□ Warfarin-based rat poison□ Tricyclics □ Others: List  Unknown□
Dose taken: if known
Accidental overdose Y □      N□ Suicide attempt Y□   N□
Other: please 
describe
Toxidrome observed Organophosphates Muscarinic Respiratory secretions□                   Sweating□ Defaecation□ Vomiting□
Urination□ Miosis□ Lacrimation□
Nicotinic Fasciculations : Y□    N□
CNS GCS:             /15      E:         /4 M:        /6 V:        /5
Alcohol Y□    N□ Glucose                                 mmol/l
Sedation Y□    N□ Sats                          %  Room Air or               %O2
Respiratory depression Y□    N□ RR                                breaths/min
Bradycardia/hypotension Y□    N□ Pulse                              beats/min
Tachycardia/Hypertension Y□    N□ BP            /                      mmHg
Seizures Y□    N□ Generalised/Focal/Other
Wide QRS complexes Y□    N□
Angioedema Y□    N□ On ACE Inhibitors Y□    N□
Attach blood gas 
results Machine where ABG done: Time of ABG
Other signs and 
symptoms observed
Time from OD to 
arrival in hospital Hours             Minutes Unknown□
Specific treatment 
instituted in MEU CPR Y□    N□
Fluids administered Ringer's□          Balsol□ 5%Dextrose water□ Saline□ Voluven□          FFP□ 5% Dextrose Saline□
Intubation Y□    N□
Induced vomiting Y□    N□
Adrenalin infusion Y□    N□ Dobutamine infusion Y□    N□
Atropine Y□    N□ 50% Dextrose Y□    N□
Bicarb Y□    N□
Other: please name
Patient disposal ICU□                High Care□ SSW □                Ward 20□ Selby□              Home□ Died□
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8.2 Appendix 2  
(Data found on Data Collection Form as put into Microsoft Excel® Document)  
DATA COLLECTION FORM  
Register 
number 
Age 
(years) 
Gender Ethnicity Type of Overdose Timing of OD Time to hospital (hours) 
    Male Female Coloured White Indian Black Other Accidental Suicide Other Month Mon Tues Wed Thurs Fri Sat Sun 
Public 
Holiday 
Actual <2 2-4 >4-24 >24 
Un-
known 
 
Toxidrome Effects 
Muscarinic Nicotinic  CNS Vital Signs Blood Results 
Resp 
Secretions 
Sweating Defecate Vomit Lacrimate Urinate Miosis Fasciculate GCS Seizures Confusion RR SBP O2 Sat RA O2 Sat on %O2 Pulse pH pH2 Potassium K2 pCO2 
 
Blood Results Continued… Treatment Disposal 
Lac BE HCO3 WCC Glucose CHE CPR 
Induced 
vomiting 
Intubated 
Adrenalin 
dose 
Dobutamine 
dose 
Atropine 
bolus 
Atropine 
Infusion 
Other ICU 
High Care 
(with 
ventilators) 
Acute Care 
(no ventilators; 
full monitoring) 
20 (limited 
monitoring 
facilities) 
Patient 
Refused 
treatment 
Died 
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8.3 Appendix 3 
 
Data 
#  
ARA 
case # 
Data 
#  
ARA 
case # 
Data 
#  
ARA 
case # 
Data 
#  
ARA 
case # 
Data 
#  
ARA 
case # 
Data 
#  
ARA 
case # 
#001   #033   #065   #097   #129   #161   
#002   #034   #066   #098   #130   #162   
#003   #035   #067   #099   #131   #163   
#004   #036   #068   #100   #132   #164   
#005   #037   #069   #101   #133   #165   
#006   #038   #070   #102   #134   #166   
#007   #039   #071   #103   #135   #167   
#008   #040   #072   #104   #136   #168   
#009   #041   #073   #105   #137   #169   
#010   #042   #074   #106   #138   #170   
#011   #043   #075   #107   #139   #171   
#012   #044   #076   #108   #140   #172   
#013   #045   #077   #109   #141   #173   
#014   #046   #078   #110   #142   #174   
#015   #047   #079   #111   #143   #175   
#016   #048   #080   #112   #144   #176   
#017   #049   #081   #113   #145   #177   
#018   #050   #082   #114   #146   #178   
#019   #051   #083   #115   #147   #179   
#020   #052   #084   #116   #148   #180   
#021   #053   #085   #117   #149   #181   
#022   #054   #086   #118   #150   #182   
#023   #055   #087   #119   #151   #183   
#024   #056   #088   #120   #152   #184   
#025   #057   #089   #121   #153   #185   
#026   #058   #090   #122   #154   #186   
#027   #059   #091   #123   #155   #187   
#028   #060   #092   #124   #156   #188   
#029   #061   #093   #125   #157   #189   
#030   #062   #094   #126   #158   #190   
#031   #063   #095   #127   #159   #191   
#032   #064   #096   #128   #160   #192   
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